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The synthesis of single enantiomers of trans-alkene  
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Abstract—   Routes to single enantiomers of hydroxy, methoxy and ketomycolic acids containing an α–methyl-trans-alkene unit as well as 
related trehalose, glucose, arabinose and glycerol esters are described. In serodiagnostic assays to detect antibodies to mycobacterial lipids, 
the trehalose esters give higher responses to the serum of patients with culture positive tuberculosis than to that of culture negative patients. 
   
Key words: Mycolic acid, TDM, TMM, GMM, trans-
alkene, trehalose monomycolate, trehalose dimycolate 
 
1. Introduction 
Mycolic acids (MAs) are characteristic components of the 
cell envelopes of mycobacteria, often covalently bound to 
arabinogalactan as a penta-arabinose tetramycolate.1-3 They 
are also seen as trehalose dimycolate (TDM – a potent 
signalling agent in the immune system),4,5 trehalose 
monomycolate (TMM)6 and other sugar esters that are not 
bound to the cell wall,7-9 or as free mycolic acids.10 MAs 
comprise two elements (Figure 1), the β-hydroxy-acid, for 
which d is generally 21 or 23, and the meromycolate. The 
latter is a long chain usually containing two groups X and 
Y.  
 
Figure 1: Typical mycolic acid structure 
 
In the most common classes of mycobacterial MA, the two 
groups are both cis-cyclopropanes (α-MA), or group X is 
an α–methyl-β-methoxy or α–methyl-β-keto group 
(methoxy and keto-MA respectively). MAs are generally 
present as complex mixtures containing several different 
chain lengths of each class, and the detailed composition is 
dependent on the mycobacterium.11,12  The presence and 
proportion of individual  classes of MA is  importan  for 
the virulence of diseases such as tuberculosis.13,14 The MAs 
are themselves strongly bioactive and indeed individual  
--------------------------------------------------------------------    
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synthetic MAs of different classes matching the structures 
of components of natural mixtures are selectively active.15 
In addition, there are a range of generally less abundant 
MAs in mycobacteria containing other X and Y groups; 
these include molecules containing an α-methyl-trans-
alkene unit.11,12 Keto-mycolic acids 2 with a proximal 
trans-alkene substituent and a variety of chain lengths have 
been reported (Table 1).11, 12,16-18 In these cases, the methyl 
group adjacent to the alkene is on the proximal side relative 
to the hydroxy-acid. The methyl group in the X positi n of 
keto- and methoxy-MA and at the Y-position in α–methyl-
trans-cyclopropane containing MA, is distal from it.11,12   
 
Table 1. Typical chain lengths of major β-methyl-trans-alkene 
containing mycobacterial ketomycolic acids (2)
 2 
Species a b c d Ref 
Mycobacterium tuberculosis,  
Mycobacterium bovis, M. bovis 
BCG, Mycobacterium microti 
17 19 15 23 11 
M. tuberculosis, M. bovis, M. 
bovis BCG, M. microti 
17 19 13 23 11 
M. tuberculosis Canetti 17 17 17 23 11 
Mycobacterium avium 
complex (MAC) 
17 17 17 21 11 
Mycobacterium  marinum 17 15 17 21 11 
Mycobacterium scrofulaceum 15 17 17 21 11 
M. aurum 15 13 19 19 19 
M. aurum 15 13 17 19 19 
 
A derivative of a hydroxy-MA with a proximal α–methyl-
trans-alkene has also been reported.16 Mycobacterium 
smegmatis synthesizes keto-MAs containing about 33% of 
















hydroxy-mycolate.20 In addition, related methoxy-MA 3 
have been reported as in Table 2.11 
 
Table 2. Typical chain lengths of major β-methyl-trans-alkene 













   
Species a b c d  
M. tuberculosis, M.  bovis, 
M. bovis BCG 
17 19 13 23  
M. tuberculosis Canetti 17 19 15 23  
M. microti 17 15 17 21  
 
The biosynthesis of these and other MA has been studied 
extensively.21-27 Labelling studies show the methyl branch 
of trans-MA from M. tuberculosis are exclusively on 
carbons derived from the 2-position of acetate,  while t ose 
from M. smegmatis, are exclusively derived from the 1-
position.28     
Another type of mycolic acid, isolated from M. smegmatis 
and Mycobacterium aurum,29 Mycobacterium chelonei,30 
and Mycobacterium fortuitum,31 contains an α–methyl-
trans-alkene at the proximal position and a cis-alkene at the 
distal position.32-34 In the latter case, the specific rotation of 
its methyl ester has been reported to be  +1.4 (CHCl3),
35 
while that of the acetoxy methyl ester is reported as +3 
(CHCl3),
  and that of a deacetoxy derivative of a mycolate 
containing only an α–methyl-trans-alkene chiral centre 
corresponds to a molecular rotation (MD) of -19.5.
35 In 
addition, the specific rotation of a wax ester containing this 
unit has been reported to be +4.3 (CHCl3).
29,36,37 This 
allows the contribution to the molecular rotation from the 
α–methyl-trans-alkene to be calculated, as the only other 
chiral centres in these cases are at the hydroxy-acid 
position, the contribution of which to the molecular 
rotation is known (+40°). This leads to a value of -25° for 
the α–methyl-trans-alkene (for 30% of methyl branched 
molecules); this in turn suggests this sub-unit has an (R)-
stereochemistry, based on model compounds.18  
 
As part of a study to determine the biological signif cance 
of specific MA structures,38-44 and to confirm regio- and 
stereochemistry, we now report the synthesis of hydroxy-
MA, keto-MA and methoxy-MA containing a α–methyl-
trans-alkene unit. Four sugar esters and one glycerol ester 
were prepared from one methoxy-MA, to provide the 
opportunity for a systematic comparison of their effects on 
cytokines and chemokines, as well as their application as 
antigens in the serodiagnosis of tuberculosis.   
 
 
2. Results and discussion 
As the first step in the synthesis of alkene-MA 23, 6-
bromohexanal (4) was chain extended to the ester 6 and 
then converted into the sulfone 7 (Scheme 1): 
 
Scheme 1: (i) LiHMDS, THF (71%); (ii) H2, Pd/C, EtOAc/EtOH (88%); 
(iii) 1-phenyl-1H-tetrazole-5-thiol, K2CO3, acetone (86%); (iv)  H2O2, 
(NH4)6Mo7O24.4H2O, THF/IMS (95%) 
 
In order to fix the (R)-stereochemistry of the α-methyl-
trans-alkene fragment, aldehyde 8,39, 45-47 was chain-
extended with compound 7 and base, using a modified 
Julia–Kocienski reaction,48-50 followed by hydrogenation of 
the derived alkenes to give 9. The pivaloate group was 
removed and the primary alcohol was converted into 
sulfone 11 (Scheme 2) via the bromide 10.  
 
Scheme 2: (i) LiHMDS, THF (86%); (ii) H2, Pd/C, EtOAc/EtOH (96%);  
(iii) KOH, THF, MeOH, H2O (97%); (iv) N-bromosuccinimide, PPh3, 
NaHCO3, CH2Cl2 (92%); (v) 1-phenyl-1H-tetrazole-5-thiol, K2CO3, 
acetone (95%); (vi) H2O2, (NH4)6Mo7O24.4H2O, THF/IMS (81%)  
  
 
A modified Julia reaction between the aldehyde 12,51,66 and 
sulfone 11 gave a mixture of alkenes which was 
hydrogenated. The silyl ether was changed to an acetyl 
group as in 13, in order to avoid the presence of two 
identical protecting groups at a later stage, and the acetal 




Scheme 3: (i) 11, LiHMDS, THF (86%); (ii) Pd/C, EtOAc (96%); (iii) 
HF.pyridine, pyridine (83%); (iv) Ac2O, pyridine (94%); (v) periodic acid 
(80%) 
 
The modified Julia–Kocienski reaction using a 1-phenyl-
1H-tetrazole sulfone and an aldehyde with potassium bis- 
(trimethylsilyl)amide in 1,2-dimethoxyethane is known to 
lead to an E-alkene with good stereoselectivity, especially 
if the sulfone or aldehyde is α-substituted.52-54 Reaction of 
the sulfone 15,60 with aldehyde 14 gave the trans-alkene 16 
(Scheme 5). It is essential that no epimerization occurs 
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considerable precedent for the retention of the chirality.53, 
56-59 Removal of the silyl group gave 17 (R= Ac, R’ = Me) 
and hydrolysis of the two esters produced the free hydroxy 
acid 17 (R= H, R’ = H). The [α]21D of this, -2.07 (CHCl3, 
0.743 µmol), corresponding to MD -26°, is in agreement 
with that reported for the hydroxymycolates of M. 
smegmatis (MD -16°, though it must be noted these only 
contain ~30% trans-alkene).18 
 
Scheme 4: (i) 14, KHMDS, 1,2-dimethoxyethane (34%); (ii) HF.pyridine, 
THF (17 (R= Ac, R’ = Me), 91%); (iii) LiOH, MeOH, THF, H2O (17 (R= 
H, R’ = H),  65%)  
 
In the same way the enantiomer of 15, compound 18,60 was 
converted into 19 and free hydroxy-MA 20 (Figure 1). The 
1H NMR spectra of each of these in the alkene region was 
identical to that reported in the literature,20,24 and to minor 






Oxidation of either 17 (R= Ac, R’ = Me) or 19 led to the 
corresponding protected keto-MAs. However, attempted 
deprotection of these using LiOH led to epimerization at 
the position adjacent to the ketone. In order to avid this, 
the alcohol 17 (R= Ac, R’ = Me) was first protected as 
THP-ether 21, followed by hydrolysis of the esters and then 
reprotection at the alcohol group as a silyl ether 22.
Removal of the THP-group, oxidation, and then 
deprotection now proceeded without epimerization,60 
leading  to the free acid 23 (Scheme 4), matching the 
overall structure of the major t ans-alkene keto-mycolate 
reported for M. marinum.11 
 
 
Scheme 4: (i) LiOH, MeOH, H2O, THF (72%); (ii) TBDMSCl, imidazole, 
DMF; (iii) K 2CO3, MeOH/H2O, then KHSO4, (70%); (iv) PPTS, MeOH, 
H2O, THF (73%); (v) PCC (89%); (vi) HF.pyridine (44%) 
 
In the same way compound 19 was first protected with a 
tetrahydropyranyl group to give 24 and then converted into the 























Scheme 5: (i) LiOH, MeOH, H2O, THF (72%); (ii) TBDMSCl, imidazole, 
DMF; (iii) K 2CO3, MeOH/H2O, then KHSO4, (70%); (iv) PPTS, MeOH, 
H2O, THF (73%); (v) PCC (89%); (vi) HF.pyridine (44%) 
  
The chain lengths reported for major t ans-alkene-
methoxy-MA are somewhat different from the keto-
analogues. In order to prepare the methoxy-MA 3 (a = 17, b 
= 19, c = 13, d = 23), aldehyde 8 was treated with 26 and 
base, followed by hydrogenation to produce 27, which was 
in turn converted into sulfone 28 by standard methods 
(Scheme 6): 
 
Scheme 6: (i) LiHMDS, THF (76 %); (ii) Pd/C,H2, EtOAc (92 %); (iii) 
LiAlH 4, THF (81 %); (iv) diethyl azodicarboxylate, Ph3 , 1-phenyl-1H-
tetrazole-5-thiol (84 %); (v) (NH4)6Mo7O24.4H2O, H2O2, THF/IMS (84 %). 
 
A further modified Julia reaction on the sulfone 28 and 
aldehyde 29,43 again followed by hydrogenation, then 
















Scheme 7: (i) LiHMDS, THF (96 %); (ii) Pd/C,H2 (96 %); (iii) periodic 
acid (87 %). 
 
The S-methoxy-S-methyl substituted aldehyde 32,39 was 
chain extended to sulfone 34, again using standard 
procedures (Scheme 8): 
 
Scheme 8: (i) LiHMDS, THF, (85 %); (ii) Pd/C,H2, (100 %); (iii) LiAlH4, 
THF (99 %); (iv) diethyl azodicarboxylate, Ph3P, 1-phenyl-1H-tetrazole-5- 
thiol (91%); (v) (NH4)6Mo7O24-4H2O, H2O2 (35%), THF/IMS (97 %). 
 
A modified Julia reaction between sulfone 34 and aldehyde 
31 led, after deprotection, to the final MA, 37.(Scheme 8) 
 
 
Scheme 8: (i) KHMDS, 1,2-dimethoxyethane (37 %); (ii) HF-pyridene, 
THF (96 %); (iii) LiOH, MeOH, H2O, THF (82 %). 
 
These results provide the first synthetic approaches to keto-
, hydroxy- and methoxy-MAs containing a proximal (R)-
α–methyl-trans-alkene unit, and a comparison of molecular 
rotations with those in the literature confirms the 
stereochemistry of this subunit. It has been proposed that 
MA biosynthesis involves alkylation of a cis-alkene by 
SAM (S-adenosylmethionine) to provides an intermediate 
cation  leading to each of the other MA functionalities.61  
Although the actual mechanism may be different,27 this 
provides a model by which to analyse the stereochemistry 
of the various classes of MA. Thus, using 38 as a model 
precursor, formal addition of a methyl cation to the distal 
carbon of the alkene from the bottom face would produce 
cation 39; trapping from the top face could lead eventually 
to the known (S,S)-stereochemistry of 40 at the distal 
position. (Scheme 9). 16, 21 
 
Scheme 9: Formation of S,S-methoxy-MA fragment 
 
Elimination of a proton from 39 would lead to 41, and in a 
second step to the proximal α–methyl-trans-cyclopropane 
unit 42 (Scheme 10). 21-26, 39 In this case, it appears that 
rapid cyclopropanation occurs, as the alkenes 41 are not 
commonly reported.     
 
Scheme 10: Formation of trans-cyclopropane 
 
In applying this to the stereochemistry of trans-alkene 
mycolates, one possibility is that alkylation of the cis-
alkene 38, again occurs from the bottom face, this time to 
the proximal carbon leading formally to 39b; elimination 
of a proton would then lead to the (R)-α–methylalkene 43 
(Scheme 11). In this case, it appears that cyclopropanation 
of the alkene does not occur, as no such regioisomers have 
been reported. 
Scheme 11: Proposed stereochemistry of methylation by SAM    
 
The biological activity of mycolic acids is often seen most 
strongly in their sugar esters, such as glucose mycolate 
(GMM), TDM and TMM.3 In natural isolates it is difficult 
to identify within the complex mixtures whether particular 
sub-classes or chain lengths are selectively responsible for 
these properties. To try to understand whether rans-alkene 
mycolic acids have specific biological properties, a series 
of sugar esters of the methoxy-MA 37 was prepared. The 
acid was first reprotected at the β-hydroxy group with 
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Scheme 12: (i) EDCl, 4-DMAP, CH2Cl2, 4 oA MS, rt, 6 days; 46 (25%), 
47 (50%). 
 
The protecting groups were then removed in two steps 
(Scheme 13):  
 
   
Scheme 13: (i) TBAF, THF, 5 oC 1h; (ii) Pyridine, THF, HF-pyridine 
complex, 43 oC, 17 h, then neutralised with aq. NaHCO3 
 
The acid 37 was also coupled to protected glucose 52 to 
give, after debenzyation, the GMM 54. (Scheme 14) 
 
 
Scheme 14: (i) CsHCO3, DMF:THF, 70 %, (ii) Na/NH3, 47 %.  
 
It was also coupled to the protected arabinose 55. (Scheme 
15)  
 
Scheme 15: (i) CsHCO3, DMF:THF, 71 %, (ii) Na/NH3, 57 %.   
 
As a final comparison, the glycerol ester (GroMM) 60 was 
prepared. (Scheme 16). 
 
 
Scheme 16: (i) CsHCO3, DMF:THF, 89 %, (ii) Na/NH3, 40 %.  
Like sugar esters of other synthetic alpha-, keto- and 
methoxy-mycolic acids, the sugar esters of trans-alkene 
methoxy described above show strong effects on a rage of 
cytokines and chemokines.63 Such sugar esters are also 
antigenic to antibodies in serum of patients infected with 
active TB.64 The trans-alkene sugar esters described above 
were each evaluated as antigens in ELISA for responses to 
antibodies in serum of patients infected with pulmonary 
tuberculosis, using modified IgG(Fc) as secondary antibody 
to provide a colour response. Twenty samples from a WHO 
Specimen Bank were used, 9 culture and smear positive for 
TB, 11 smear and culture negative and diagnosed as not 
having TB. The samples were all from patients showing 
symptoms of suspected TB.65 The results are presented in 
Table 1s (Supplementary Information) and the average 















Graph 1: Average responses and standard deviations for 9 serum samples 
from pulmonary TB, culture and smear positive patients (TB+) and 11 
from culture and smear negative patients (TB0) from the WHO TDR TB 
specimen Bank,65 clinically diagnosed using standard protocols in ELISA 
assay using IgG(Fc) secondary antibody 
Although the standard deviations within this small sample 
set are large, these results indicate that the synthetic alkene 
containing TDM 49 and TMM 51 may offer potential in the 
diagnosis of active TB. It is interesting that, forthis series 
of compounds, the GMM 54, GroMM 60 and ArMM 57 do 
not show significant distinction between pulmonary TB 
positive or negative samples. An extended study using a 
large serum set is now under way to evaluate these 
molecules compared to other synthetic sugar mycolates s 
antigens in diagnosis. 
 
3. Experimental section 
3.1 Chemicals were obtained from commercial suppliers 
(Sigma, Aldrich, and Alfa Aeser) or prepared from them by 
the methods described. Solvents which were required to be 
dry, e.g. ether, tetrahydrofuran were dried over sodium wire 
and benzophenone under nitrogen, while CH2 l2 was dried 
over calcium hydride. All reagents and solvents used w re 
of reagent grade unless otherwise stated. Silica gel (M rck 
7736) and silica gel plates used for column chromatgr phy 
and thin layer chromatography were obtained from Aldrich; 
separated components were detected using variously UV 
light, I2 and phosphomolybdic acid solution in IMS 
followed by charring. Anhydrous magnesium sulfate was 
used to dry organic solutions. Infra-red (IR) spectra were 
carried out on a Perkin-Elmer 1600 F.T.I.R. spectrometer 
as liquid films or KBr disc (solid). Melting points were 
measured using a Gallenkamp melting point apparatus. 
NMR spectra were carried out on a Bruker Avance 400 or 
500 spectrometer. Specific rotations were recorded in 
CHCl3 on a POLAAR 2001 Optical Activity Polarimeter. 
Mass spectra were recorded on a Bruker matrix-assisted 
laser desorption/ ionisation-time of flight mass 
spectrometry (MALDI-TOF MS) values are given plus 
sodium to an accuracy of 1 d.p.; accurate mass values were 
run on a Bruker LC-MS or on MALDI-TOF MS in Bristol 
University. 
The detailed procedures for the preparation of compounds 7 
– 11 are provided in the Supplementary Information.  
Serum samples, provided by the World Health Organisation 
from the TDR TB Specimen Bank with the necessary 
ethical approval,65 were all from individuals with 
symptoms of suspected tuberculosis.  
3.2 (R)-2-[(1R,19R)-1-(tert-Butyldimethylsilanyloxy)-19 
(R)-2-[(1R,19R)-1-acetoxy-19-((S)-2,2-dimethyl[1,3]di-
oxolan-4-yl)-eicosyl]tetracosanoic acid methyl ester 13 
(i) LiHMDS (8.50 mL, 8.76 mmol, 1.06 M) was added to a 
stirred solution of  ester 12 (2.62 g, 4.61 mmol)66 and  
tetrazole 11 (2.78 g, 5.07 mmol) in dry THF (50 mL) at –5 
oC under nitrogen. The mixture was allowed to reach r. t., 
stirred for 30 min. Then quenched with sat. aq. NH4Cl (10 
mL) and extracted with EtOAc and petrol (5:1, 3 × 50 mL). 
The combined organic layers were washed with water (25 
mL), dried, and evaporated; chromatography (petrol/ether, 
15:1) gave a colourless oil, methyl (R)-2-[(E/Z)-(1R,19R)-
1-(tert-butyldimethylsilanyloxy)-19-((S)-2,2-
dimethyl[1,3]di-oxolan-4-yleicos-3-enyl]tetracosanote (3.6 
g, 86%) as a mixture of isomers in ratio 2.2:1. Palladium 
10% on carbon (1.0 g) was added to a stirred solution of the 
alkenes (3.45 g, 3.88 mmol) in EtOAc (150 mL). 
Hydrogenation was carried out for 1.5 h. The solutin was 
filtered over a bed of celite and the solvent was evaporated. 
Chromatography (petrol/ether, 15:1) gave a colourless oil, 
(R)-2-[(1R,19R)-1-(tert-butyl-dimethylsilan-yloxy)-19-((S)-
2,2-dimethyl[1,3]-dioxolan-4-yl)eicosyl]-tetracosanoic acid 
methyl ester (3.2 g, 96%), [α] 22
D
+3.6 (c 0.94, CHCl3) 
[Found (M+H)+: 893.8321, C56H113O5Si requires: 
893.8352]; δH (500 MHz, CDCl3): 4.0 (1H, dd, J 6.3, 7.9 
Hz), 3.93 – 3.90 (1H, m), 3.87 (1H, br q, J 7.0 Hz), 3.66 
(3H, s), 3.61 (1H, br t, J 7.9 Hz), 2.53 (1H, ddd, J 3.8, 7.3, 
11.1 Hz), 1.59 – 1.52 (4H, m), 1.41 (3H, s), 1.36 (H, s), 
1.35 – 1.26 (72H, m, v.br), 1.10 – 1.07 (1H, m), 0.97 (3H, 
d, J 6.6 Hz), 0.89 (3H, t, J 6.9 Hz), 0.87 (9H, s), 0.05 (3H, 
s), 0.03 (3H, s); δC (126 MHz, CDCl3): 175.1, 108.5, 80.4, 
76.8, 73.2, 51.6, 51.2, 36.5, 33.7, 32.7, 31.9, 29.9, 29.8, 
29.7(v.br), 29.66, 29.62, 29.6, 29.58, 29.5, 29.4, 29.3, 27.8, 
27.5, 27.0, 26.6, 25.7, 25.5, 23.7, 22.7, 18.0, 15.6, 14.1, – 
4.4, – 4.9; νmax/cm
-1: 2925, 2854, 1741, 1465, 1368, 1253, 
1165, 1068. 
(ii) The above ester (3.22 g, 3.61 mmol) was stirred in dry 
THF (30 mL) in dry polyethylene vial under nitrogen at 0 
°C. Pyridine (1.2 mL) and HF.pyridine complex (5.0 mL) 
were added and the mixture was stirred for 18 h at 45 °C. 
The mixture was neutralised by slowly pouring it into sat. 
aq. NaHCO3 (20 mL). The product was extracted with 
petrol/EtOAc (5:1, 3 × 10 mL), and evaporated to give a 
white solid. Chromatography (5:1 petrol/EtOAc) gave a 
white solid, methyl (R)-2-[(1R,19R)-19-((S)-2,2-dimethyl-
[1,3]dioxolan-4-yl)-1-hydroxyeicosyl]tetracosanoate (2.3 g, 
83%), m.p. 67 – 68 oC, [α] 25
D
+14.8 (c 0.970, CHCl3) [Found 
(M+H)+: 779.7450, C50H99O5 requires: 779.7487]. This 
showed δH  (500 MHz, CDCl3): 4.0 (1H, dd, J 6.3, 7.9 Hz), 
3.87 (1H, br q, J 6.9 Hz), 3.71 (3H, s), 3.68 – 3.64 (1H, m), 
3.60 (1H, br t, J 7.7 Hz), 2.44 (1H, dt, J 5.4, 10.4 Hz), 1.74 
– 1.26 (77H, m, v br), 1.41 (3H, s), 1.36 (3H, s), 1.11 – 
1.07 (1H, m), 0.96 (3H, d, J 7.0 Hz), 0.88 (3H, t, J 7.0 Hz); 
δC (126 MHz, CDCl3): 176.2, 108.5, 80.4, 72.3, 67.8, 51.5, 
50.9, 36.5, 35.7, 32.7, 31.9, 29.9, 29.7(v.br), 29.65, 29.62, 
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26.6, 25.7, 25.5, 22.7, 15.6, 14.1; νmax/cm
-1: 3520, 2924, 
2854, 1710, 1461, 1377, 1264, 1189, 1164. 
(iii) A mixture of acetic anhydride (20 mL) and anhydrous 
pyridine (20 mL) was added with stirring to the above ester 
(2.24 g, 2.88 mmol) in dry toluene (15 mL), stirred for 20 h 
at r.t, then diluted with toluene (20 mL); the solvent was 
removed under reduced pressure to give an oil. Chroma-
tography (petrol/EtOAc, 5:1) gave a white solid,   
compound 13 (2.2 g, 94%), m.p. 37 – 38 oC, [α] 25
D
+15.5 (c 
1.03, CHCl3) [Found (M+Na)
+: 843.7431, C52H100NaO6 
requires: 843.7412]; δH (500 MHz, CDCl3): 5.11 – 5.07 
(1H, m), 4.01 (1H, dd, J 6.0, 7.9 Hz), 3.88 (1H, br q, J 6.9 
Hz), 3.69 (3H, s), 3.61 (1H, br t, J 7.7 Hz), 2.62 (1H, ddd, J 
4.4, 6.9, 10.9 Hz), 2.04 (3H, s), 1.62 – 1.26 (76H, m, v.br), 
1.41 (3H, s), 1.36 (3H, s), 1.13 – 1.06 (1H, m), 0.96 (3H, d, 
J 7.0 Hz), 0.89 (3H, t, J 7.0 Hz); δC (126 MHz, CDCl3): 
173.6, 170.3, 108.5, 80.4, 74.1, 67.8, 51.5, 49.6, 36.5, 32.7, 
31.9, 31.7, 29.9, 29.7(v.br), 29.64, 29.61, 29.54, 29.46, 
29.42, 29.4, 29.3, 28.1, 27.5, 27.0, 26.6, 25.5, 25.0, 22.7, 
21.0, 15.6, 14.1; νmax/cm
-1: 2924, 2854, 1747, 1465, 1369, 
1236, 1163, 1066. 
 
3.3 (R)-2-((1R,19R)-1-Acetoxy-19-methyl-20-oxoeicosyl)- 
tetracosanoic acid methyl ester 14 
Periodic acid (1.0 g, 4.4 mmol) was added to the acetal 13 
(1.20 g, 1.46 mmol) in dry ether (60 mL) at r.t. under argon 
and stirred for 18 h. The mixture was filtered through celite 
and washed with ether. The solvent was evaporated; 
chromatography eluting with petrol/EtOAc (4:1) gave a 
white solid, the title compound 14 (0.87 g, 80%), m.p. 31 – 
31 oC, [α] 23
D
 +3.2 (c 0.69, CHCl3) [Found (M+Na)
+: 
771.6834, C48H92NaO5 requires: 771.6837]. This showed δH 
(500 MHz, CDCl3):  9.62 (1H, d, J 1.9 Hz), 5.11 – 5.07 
(1H, m), 3.68 (3H, s), 2.62 (1H, ddd, J 4.1, 7.0, 10.4 Hz), 
2.33 (1H, d sext, J 1.9, 7.0 Hz), 2.03 (3H, s), 1.73 – 1.26 
(76H, m, v.br), 1.09 (3H, d, J 7.0 Hz), 0.88 (3H, t, J 7.0 
Hz); δC: 205.4, 173.7, 170.3, 74.1, 51.5, 49.6, 46.3, 31.9, 
31.7, 30.5, 29.7(v.br), 29.62, 29.6, 29.54, 29.5, 29.4 , 29.4, 
29.3, 28.1, 27.5, 26.9, 25.0, 22.7, 21.0, 14.1, 13.3; νmax/cm
-
1: 2922, 2852, 1744, 1467, 1372, 1237, 1167, 1022. 
 
3.4 (2R,3R,21R,39S,40S,E)-2-Docosyl-3,39-dihydroxy-
21,40-dimethyloctapentacont-22-enoic acid 17 (R = R’ = 
H) 
(i) Ester 14 (0.24 g, 0.32 mmol) in dry 1,2-
dimethoxyethane (10 mL) was added to a stirred solution of 
sulfone 15 (0.34 g, 0.40 mmol)60 in dry 1,2-
dimethoxyethane (20 mL) at r.t under nitrogen. The 
mixture was cooled to –20 °C and KHMDS (1.04 mL, 
0.520 mmol, 0.5 M in toluene) was added, then allowed to 
reach r.t and stirred for 1.5 h. Sat. aq. NH4Cl (25 mL) and 
petrol/ ether (1:1, 50 mL) were added. The aqueous layer 
was re-extracted with petrol/ether (1:1, 2 × 40 mL) and the 
combined organic layers were evaporated. Chromatogrphy 
(petrol/ether, 20:1) gave a white solid, methyl 
(2R,3R,21R,39S,40S,E)-3-acetoxy-39-((tert-butyl-
dimethylsilyl)oxy)-2-docosyl-21,40-dimethyloctapenta-
cont-22-enoate 16 (0.15 g, 34%), m.p.  25 – 27 °C, [α] 23
D
 –
3.18 (c 0.875, CHCl3) [MALDI-Found M+Na
+: 1404.2; 
C91H180NaO5Si requires: 1404.3] which showed δH (500 
MHz, CDCl3): 5.34 (1H, dt, J 6.7, 15 Hz), 5.23 (1H, dd, J 
7.5, 15 Hz), 5.09 (1H, ddd, J 4.1, 7.23, 8.2 Hz), 3.68 (3H, 
s), 3.49 (1H, dt, J 3.5, 6.3 Hz), 2.62 (1H, ddd, J 4.4, 7.0, 
11.0 Hz), 2.05 (3H, s), 1.99 (2H, q, J 7 Hz), 1.70 – 1.20 
(139H, br m including br s at 1.27), 1.08 – 1.00 (1H, m), 
0.93 (3H, d, J 7 Hz), 0.89 (6H, t, J 6.7 Hz), 0.88 (9H, s), 
0.80 (3H, d, J 7 Hz), 0.04 (3H, s), 0.03 (3H, s); δC (126 
MHz, CDCl3): 173.6, 170.3, 136.5, 128.4, 75.9, 74.1, 51.5, 
49.6, 37.7, 37.2, 36.7, 33.5, 32.6, 32.5, 31.9, 31.7, 30.0, 
29.9, 29.8, 29.7, 29.67, 29.62, 29.6, 29.54, 29.5, 29.43, 
29.41, 29.4, 29.1, 28.1, 27.7, 27.5, 27.4, 26.0, 25.9, 25.0, 
22.7, 21.0, 20.9, 18.2, 14.4, 14.1, –4.2, –4.4; υmax: 2923, 
2853, 1745, 1464 cm-1. 
(ii) Compound 16 (150 mg, 0.108 mmol) was dissolved in 
dry THF (8 mL) under nitrogen in a dry polyethylene vial, 
equipped with a rubber septum, at 0 °C. Pyridine (0.1 mL) 
and HF-pyridine complex (0.4 mL) were added and the 
mixture stirred for 18 h at 45 °C, then neutralized by slowly 
pouring it into sat. aq. NaHCO3 (10 mL) until no more 
carbon dioxide was liberated. The product was extracted 
with petrol/ether (1:1, 3 × 25 mL), dried and evaporated to 
give a white solid. Chromatography (petrol/ether, 10:1) 
gave a white solid, methyl (2R,3R,21R,39S,40S,E)-3-
acetoxy-2-docosyl-39-hydroxy-21,40-dimethyloctapenta-
cont-22-en-oate 17 (R = Ac, R’ = Me) (138 mg, 92%), [α]
23
D
 –3.59 (c 1.04, CHCl3); m.p. 36 – 38 °C [MALDI-Found 
M+Na+: 1290.2; C85H166NaO5 requires: 1290.2]; δH (500 
MHz, CDCl3): 5.33 (1H, dt, J 6.6, 15.5 Hz), 5.24 (1H, dd, J 
7.6, 15.5 Hz), 5.09 (1H, dt, J 3.9, J 8 Hz), 3.69 (3H, s), 3.53 
– 3.49 (1H, m), 2.62 (1H, ddd, J 4.4, 7, 10.9 Hz), 2.04 (3H, 
s), 1.98 (2H, q, J 7 Hz), 1.63 –1.20 (140H, br m including 
br s at 1.27), 1.18 – 1.11 (1H, m), 0.94 (3H, d, J 6.6 Hz), 
0.89 (6H, t, J 6.7 Hz), 0.86 (3H, d, J 7 Hz); δC (126 MHz, 
CDCl3): 173.6, 170.3, 136.5, 128.4, 75.3, 74.1, 51.5, 49.6, 
38.3, 37.2, 36.7, 34.5, 33.5, 32.6, 31.9, 31.7, 30.0, 29.9, 
29.8, 29.72, 29.7, 29.63, 29.6, 29.5, 29.45, 29.44, 29.42, 
29.4, 29.1, 28.1, 27.7, 27.5, 27.4, 27.3, 26.2, 25.0, 22.7, 
21.0, 20.9, 18.2, 14.4, 13.6; υmax: 3542, 2923, 2843, 1745, 
1464 cm-1. 
(iii) Lithium hydroxide monohydrate (17.04 mg, 0.7102 
mmol, 30 mol. equiv.) was added to a stirred solutin of  
ester 17 (R = Ac, R’ = Me) (30.0 mg, 0.0237 mmol) in 
THF (3 mL), methanol (0.5 mL) and water (0.5 mL) at RT. 
The mixture was stirred at 43 °C for 18 h, then cooled to 
RT and acidified with hydrochloric acid (5 %, 2 mL) and 
the aqueous layer was extracted with warm petrol/ether 
(1:1, 3 × 10 mL). The combined organic extracts were dried 
and evaporated; column chromatography (warm 
petrol/EtOAc, 5:1) gave a white solid,   acid 17 (R = R’ = 
H) (18.6 mg, 65%), [α]21D –2.1 (CHCl3, 0.74 µmol) 
[MALDI-Found M+Na+: 1234.3; C82H162NaO4 requires: 
1234.2]; δH (500 MHz, CDCl3): 5.33 (1H, dt, J 6.6, 15.5 
Hz), 5.23 (1H, dd, J 7.6, 15.5 Hz), 3.70 – 3.69 (1H, m), 
3.52 – 3.51 (1H, m), 2.45 (1H, br pent, J 4.7 Hz), 2.05 – 
2.00 (1H, m), 1.97 (2H, q, J 6.9 Hz), 1.79 – 1.71 (1H, m), 
1.66 – 1.59 (2H, m), 1.64 – 1.23 (139H, br m, including br 
s at 1.26), 0.94 (3H, d, J 6.6 Hz), 0.89 (6H, t, J 7.0 Hz), 
0.86 (3H, d, J 7.3 Hz); δC (126 MHz, CDCl3): 177.3, 136.5, 
128.5, 75.4, 72.2, 50.5, 37.3, 36.7, 34.4, 33.4, 32.6, 31.9, 
30.0, 29.7, 29.6, 29.52, 29.5, 29.4, 29.1, 27.4, 22.7, 1.0, 

















dimethyl-39-oxooctapentacont-22-enoic acid 23 
(i) 2,3-Dihydropyran (0.18 mL, 2.0 mmol) and pyridinium-
p-toluene sulfonate (120 mg, 0.0510 mmol) were added to 
a stirred solution of the ester 17 (R = Ac) (130 mg, 0.101 
mmol) in dry CH2Cl2 (1 mL) under nitrogen at r.t. The 
mixture was stirred for 1 h, then quenched with sat. aq. 
NaHCO3 (3 mL) and extracted with CH2Cl2 (2 × 15 mL). 
The combined organic layers were washed with water (5 
mL) and evaporated to give an oil; chromatography 
(petrol/EtOAc, 10:1) gave a colourless oil, methyl (2R, 
3R,21R,39S,40S,E)-3-acetoxy-2-docosyl-21,40-dimethyl-
39-((tetrahydro-2H-pyran-2-yl)oxy)octapenta-cont-22-en-
oate 21 (128 mg, 92%) as a mixture of diastereoisomers 
[MALDI-Found M+Na+: 1374.2; C90H174NaO6 requires: 
1374.3]; δH (400 MHz, CDCl3): 5.33 (1H, dt, J 6.7, 15.2 
Hz), 5.24 (1H, dd, J 7.6, 15.2 Hz), 5.11 – 5.07 (1H, m), 
4.65 (0.5H, br t, J 2.8 Hz), 4.62 (0.5H, br t, J 2.6 Hz), 3.96 
– 3.89 (1H, m), 3.68 (3H, s), 3.50 – 3.44 (2H, m), 2.63 (1H, 
ddd, J 4.7, 6.7, 10.8 Hz), 2.1 – 2.0  (4H, including s at 
2.03), 1.97 (2H, q, J 6.6 Hz), 1.86 – 1.82 (1H, m), 1.59 – 
1.14 (144H, br m including br s at 1.26), 0.94 (3H, d, J 6.7 
Hz), 0.89 (6H, t, J 6.6 Hz), 0.84 (3H, d, J 6.7 Hz); δC (126 
MHz, CDCl3): 173.7, 170.3, 136.5, 128.4, 98.5, 97.8, 81.4, 
80.9, 74.1, 62.7, 62.4, 51.5, 49.6, 37.2, 36.7, 36.4, 35.1, 
32.6, 32.5, 32.0, 31.9, 31.7, 31.4, 31.3, 31.2, 29.94, 29.9, 
29.8, 29.7, 29.65, 29.6, 29.5, 29.42, 29.4, 29.35, 29.1, 28.1, 
27.8, 27.5, 27.4, 27.3, 26.1, 25.7, 25.66, 25.6, 25.0, 22.7, 
21.0, 20.9, 20.1, 19.8, 15.2, 14.9, 14.1; υmax: 2924, 2853m, 
2360m, 2341m, 1464 cm-1.  
(ii) Lithium hydroxide monohydrate (37 mg, 0.88 mmol.) 
was added to a stirred solution of ester 21 (120 mg, 0.088  
mmol) in THF (8 mL), methanol (1.0 mL) and water (1.5 
mL) at r.t. The mixture was stirred at 45 °C for 18 h, then 
cooled to r.t., acidified with hydrochloric acid (5%, 2 mL 
pH 6) and extracted with warm petrol/EtOAc (5:2, 3 × 10 
mL). The combined organic extracts were evaporated; 
chromatography (5:1 petrol/EtOAc) gave a white solid, 
(2R, 3R,21R,39S,40S,E)-2-docosyl-3-hydroxy-21,40-
dimethyl-39-((tetrahydro-2H-pyran-2-
yl)oxy)octapentacont-22-enoic acid as a mixture of 
diastereoisomers (100 mg, 90%) [MALDI-Found (M+Na)+: 
1318.1; C87H170NaO5 requires: 1318.2]; δH (400 MHz, 
CDCl3): 5.33 (1H, dt, J 6.44, 15.4 Hz), 5.25 (1H, dd, J 7.4, 
15.4 Hz), 4.67 (0.5H, br t, J 3.1 Hz), 4.44 (0.5H, br t, J 3.9 
Hz), 3.97 – 3.89 (1H, m), 3.71 (1H, br q, J 6.7 Hz), 3.55 – 
3.43 (2H, m),  2.45 (1H, br dt, J 5.3, 8.6 Hz), 2.05 – 2.03 
(1H, br, m), 1.97 (2H, q, J 6.5 Hz), 1.91 – 1.03 (147H, br, 
m), 0.93 (3H, d, J 6.7 Hz), 0.88 (6H, t, J 6.3 Hz), 0.85 (3H, 
d, J 6.9 Hz); δC (126 MHz, CDCl3): 179.7, 136.4, 128.4, 
98.4, 97.7, 81.5, 81.0, 72.1, 62.6, 62.3, 50.8, 37.2, 36.7, 
35.5, 32.5, 31.9, 31.2, 29.9, 29.8, 29.7, 29.6, 29.53, 29.5, 
29.4, 29.3, 29.1, 27.3, 25.7, 25.6, 22.6, 20.9, 15.1, 14.9, 
14.1; υmax: 3424, 2922, 2852, 2361, 1646 cm
-1. 
(iii) Imidazole (510 mg, 0.756 mmol) was added to a stirred 
solution of the above acid (98.0 mg, 0.076 mmol) in dry 
DMF (1.5 mL) and dry toluene (2.5 mL) at RT followed by 
addition of TBDMSCl (0.110 mg, 0.756 mmol) and DMAP 
(14.0 mg, 0.115 mmol). The mixture was heated to 70 °C 
for 18 h; it was then diluted with petrol/EtOAc (1:1, 15 
mL) and sat. aq. NaHCO3 (3 mL). The aqueous layer was 
re-extracted with petrol/EtOAc (3 × 15 mL), and 
evaporated. The residue was dissolved in THF (6 mL), 
methanol (1.0 mL) and water (1.5 mL); to this, potassium 
carbonate (300 mg) was added and the mixture stirred at 45 
°C for 2 h. The mixture was diluted with petrol/EtOAc 
(1:1, 10 mL) and water (1 mL) and acidified with 
potassium hydrogen sulfate to pH 6. The aqueous layer was 
re-extracted with petrol/EtOAc (5:2, 2 × 10 mL), the 
combined organic layers were dried and evaporated. 
Chromatography (petrol/EtOAc, 20:1) gave a colourless 
oil, (2R,3R,21R,39S, 40S,E)-3-((tert-butyldi-methylsilyl)-
oxy)-2-docosyl-21,40-dimethyl-39-((tetra-hydro-2H-pyran-
2-yl)oxy)octapentacont-22-enoic acid 22 (84 mg, 84%) as a 
mixture of diastereisomers [MALDI-Found M+Na+: 
1433.5; C93H184NaO5Si requires: 1433.5]; δH (400 MHz, 
CDCl3): 5.34 (1H, dt, J 6.6, 15.2 Hz), 5.24 (1H, dd, J 7.6, 
15.2 Hz), 4.67 (0.5H, br d, J 2.9 Hz), 4.62 (0.5H, br t, J 4.5 
Hz ), 3.96 – 3.89 (1H, m), 3.86 – 3.82 (1H, m), 3.50 – 3.42 
(2H, m), 2.55 – 2.51 (1H, ddd, J 3.3, 5.6, 12.6 Hz), 2.07 – 
2.01 (1H, m), 1.97 (2H, q, J 7.3 Hz), 1.85 – 1.80 (1H, m), 
1.75 – 1.1 ( 145H, br m), 0.93 (3H, d, J 6.8 Hz), 0.90 (9H, 
s), 0.87 (6H, t, J 6.6 Hz), 0.84 (3H, d, J 7.0 Hz), 0.14 (3H, 
s), 0.13 (3H, s); δC (126 MHz, CDCl3): 171.0, 136.4, 128.3, 
98.5, 97.8, 81.4, 80.9, 73.5, 62.7, 62.4, 50.7, 37.2, 36.7, 
36.4, 35.1, 34.9, 32.6, 32.4, 32.0, 31.9, 31.4, 31.2, 31.17, 
30.1, 30.0, 29.82, 29.8, 29.73, 29.7, 29.6, 29.57, 29.52, 
29.5, 29.42, 29.4, 29.1, 29.0, 27.7, 27.4, 27.38, 26.3, 25.8, 
25.7, 25.2, 22.73, 22.7, 22.6, 21.1, 20.9, 20.4, 19.4, 18.8, 
17.8, 14.3, 14.1, 13.6, 11.4, 4.3, –4.9; υmax: 3425, 2924, 
2853, 2362, 1702, 1464 cm-1. 
(iv) Pyridinium-p-toluene sulfonate (PPTS) (128 mg, 0.588 
mmol) was added to a stirred solution of the acid 22 (83 
mg, 0.058 mmol) in THF (3 mL), and MeOH (0.5 mL) and 
the mixture stirred at 40 °C for 6 h, then sat. aq. NaHCO3 
(0.2 mL) was added and the product extracted with 
petrol/EtOAc (1:1, 3 × 10 mL). The combined organic 
layers were evaporated to give a crude oil; chromatgr phy 
(petrol/ EtOAc, 10:1) gave a colourless oil, 
(2R,3R,21R,39S,40S,E)-3-((tert-butyldimethylsilyl)oxy)-2-
docosyl-39-hydroxy-21, 40-dimethyloctapentacont-22-
enoic acid (76 mg, 97%) [Found (M+Na)+: 1348.6; 
C88H176NaO4Si requires: 1348.3]; δH (400 MHz, CDCl3): 
5.34 (1H, dt, J 6.4, 15.3 Hz), 5.24 (1H, dd, J , 7.4, 15.3 
Hz), 3.85 (1H, br, dd, J 6.1, 9.8 Hz), 3.51 (1H, dt, J 4.5, 8.8 
Hz), 2.53 (1H, ddd, J 3.8, 5.4, 9.3 Hz), 2.03 (1H, m), 1.97 
(2H, q, J 6.6 Hz), 1.73 – 1.62 (1H, m), 1.43 – 1.26 (140H, 
br m including, s at 1.26),  0.94 (3H, d, J 6.7 Hz), 0.92 (9H, 
s), 0.88 (6H, t, J 6.8 Hz), 0.86 (3H, d, J 6.6 Hz), 0.13 (3H, 
s), 0.12 (3H, s); δC (126 MHz, CDCl3): 177.7, 136.5, 128.4, 
75.3, 73.7, 50.0, 41.4, 38.2, 37.3, 36.7, 35.8, 34.5, 33.4, 
32.6, 31.9, 31.6, 30.1, 30.0, 29.82, 29.8, 29.73, 29.7, 29.64, 
29.6, 29.52, 29.5, 29.44, 29.4, 29.1, 29.0, 27.7, 27.4, 27.37, 
26.3, 25.8, 25.7, 25.2, 22.72, 22.7, 22.6, 21.1, 20.9, 20.4, 
19.4, 18.8, 17.9, 14.3, 14.2, 14.1, 13.6, 11.4, –4.2, –4.9; 
υmax: 3424, 2923, 2852, 1709, 1464 cm
-1. 
(v) The above acid (75 mg, 0.056 mmol), in CH2 l2 (10 
mL), was added to a stirred suspension of PCC (36 mg, 
0.16 mmol) in CH2Cl2 (2 mL) at r.t. and stirred for 1 h. The 
solvent was evaporated; chromatography (petrol/EtOAc, 
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octapentacont-22-enoic acid (61 mg, 82%)  [MALDI-
Found (M+Na)+: 1346.3; C88H174NaO4Si requires: 1346.3]; 
δH (400 MHz, CDCl3): 5.34 (1H, dt, J 6.4, 15.2 Hz), 5.24 
(1H, dd, J 7.4, 15.3 Hz), 3.86 (1H, br q, J 6.1 Hz), 2.57 – 
2.46 (2H, m), 2.41 (2H, dt, J, 1.9, 7.3 Hz), 2.08 – 2.00 (1H, 
m), 1.97 (2H, q, J 6.7 Hz), 1.70 – 1.59 (2H, m), 1.60 – 1.49 
(4H, m), 1.28 (131H, s), 1.05 (3H, d, J 6.9 Hz), 0.95 (3H, d, 
J 6.7 Hz), 0.91(9H, s), 0.88 (6H, t, J 6.6 Hz), 0.12 (3H, s), 
0.11 (3H, s); δC (126 MHz, CDCl3): 215.3, 178.0, 136.5, 
128.4, 73.7, 50.0, 46.3, 41.2, 37.3, 36.7, 35.8, 33.1, 2.6, 
31.9, 29.8, 29.72, 29.7, 29.64, 29.6, 29.58, 29.54, 29.5, 
29.48, 29.46, 29.44, 29.4, 29.3, 29.22, 29.2, 27.4, 27.32, 
27.3, 25.7, 25.2, 23.7, 22.7, 20.1, 17.9, 16.4, 14.1, –4.2, –
4.9; υmax: 3419, 2925, 2854, 2360, 2341, 1711, 1464 cm
-1.  
 (vi) The above acid (10 mg, 0.0075 mmol) was dissolved 
in dry THF (4 mL) under nitrogen in a dry polyethylene 
vial equipped with a rubber septum at 0 °C. Pyridine (0.1 
mL) and HF-pyridine complex (0.32 mL, 0.022 mmol.) 
were added and the mixture stirred for 18h at 45 °C then 
neutralised by slowly pouring into sat. aq. NaHCO3 (3 mL) 
until no more carbon dioxide was liberated. The product 
was extracted with petrol/ether (1:1, 3 × 10 mL), and 
evaporated to give a white solid. Chromatography 
(petrol/EtOAc, 5:1) gave a white solid, compound 23 (9.0 
mg, 98%) [MALDI-Found (M+Na)+: 1232.2; C82H160O4Na 
requires: 1232.2]; δH (500 MHz, CDCl3): 5.32 (1H, dt, J 
6.7, 15.5 Hz), 5.24 (1H, dd, J 7.6, 15.5 Hz), 3.73 (1H, m), 
2.50 – 2.45 (2H, m), 2.42 (2H, t, J 7.0 Hz ), 2.02 (1H, m), 
1.96 (2H, q, J 6.8 Hz), 1.74 (2H, m), 1.65 – 1.51 (10H, m), 
1.26 (126H, br m), 1.05 (3H, d, J 7.0 Hz), 0.95 (3H, d, J 7.0 
Hz), 0.89 (6H, t, J 6.7 Hz); δC: 215.5, 177.9, 136.5, 128.4, 
72.2, 50.6, 46.4, 41.2, 37.3, 36.7, 35.6, 33.1, 32.6, 31.9, 
29.8, 29.7, 29.64, 29.6, 29.54, 29.51, 29.5, 29.43, 29.4, 
29.3, 29.1, 28.9, 27.4, 27.3, 25.7, 23.7, 22.7, 22.6, 1.0, 
19.4, 16.4, 14.1; υmax: 3420, 3019, 2926, 2855, 1521, 1420, 
1215 cm-1.  
 
3.6 (2R,3R,21R,40R,E)-2-Docosyl-3-hydroxy-21,40-
dimethyl-39-oxooctapentacont-22-enoic acid 25 
(i) Lithium hydroxide monohydrate (52.8 mg, 1.55 mmol, 
30 mol.equiv.) was added to a stirred solution of ester 24 
(70.0 mg, 0.0520 mmol) (see Supplementary Information) 
in THF (5 mL), methanol (0.5 mL) and water (0.5 mL) at 
RT. The mixture was stirred at 43 °C for 18 h, then cooled 
to RT and acidified with hydrochloric acid (5%, 2 mL) and 
the aqueous layer extracted with warm petrol/ether (1:1, 3 × 
10 mL). The combined organic extracts were dried an
evaporated; chromatography eluting with petrol/EtOAc 
(5:2) gave a semi solid, (2R,3R,21R, 39R,40R,E)-2-
docosyl-3-hydroxy-21,40-dimethyl-39-((tetrahydro-2H-
pyran-2-yl)oxy)octapenta-cont-22-enoic acid (46.0 mg, 
72%), [α]22D +1.75 (c 1.19 µmol, CHCl3) [MALDI-Found 
(M+Na)+: 1318.1; C87H170NaO5 requires: 1318.3]; which 
showed δH (500 MHz, CDCl3): 5.33 (1H, dt, J 6.7, 15.2 
Hz), 5.24 (1H, dd, J 7.6, 15.2 Hz), 4.67 (0.5H, br t, J 3.1 
Hz), 4.44 (0.5H, br t, J 3.8 Hz), 3.97 – 3.89 (1H, m), 3.71 
(1H, br q, J 6.7 Hz), 3.55 – 3.43 (2H, m),  2.49 – 2.42 (1H, 
m), 2.05 – 2.03 (1H, m), 1.97 (2H, q, J 7.3 Hz), 1.88 – 1.82 
(1H, m), 1.63 – 1.21 (146H, br m including br s at 1.26), 
0.94 (3H, d, J 6.7 Hz), 0.89 (6H, t, J 6.6 Hz), 0.84 (3H, d, J
6.7 Hz); δC (126 MHz, CDCl3): 177.5, 145.5, 136.5, 72.2, 
67.4, 60.4, 50.5, 37.3, 36.7, 35.6, 34.5, 32.6, 31.9, 30.9, 
30.3, 30.1, 30.0, 29.9, 29.7, 29.6, 29.5, 29.42, 29.4, 29.3, 
29.12, 29.1, 28.9, 28.1, 27.3, 26.1, 25.8, 22.7, 22.6, 2.3, 
21.1, 21.0, 20.4, 19.4, 14.2, 14.11, 14.06; υmax: 3424, 2922, 
2852, 2361, 1646 cm-1.  
(ii) Imidazole (22.7 mg, 0.333 mmol, 10 mol. equiv.) was 
added to a stirred solution of the above acid (45 mg, 0.033 
mmol) in dry DMF (0.2 mL) at r. t. followed by addition of 
TBDMSCl (50.0 mg, 0.333 mmol, 10 mol. equiv.) and 
DMAP (4.01 mg, 0.0333 mmol). The mixture was heated 
to 70 °C for 18 h, then diluted with petrol/EtOAc (1:1, 15 
mL) and sat. aq. NaHCO3 (3 mL). The aqueous layer was 
re-extracted with petrol/EtOAc (3 × 15 mL), and the 
solvent evaporated. The residue was dissolved in THF (5 
mL), methanol (0.5 mL) and water (0.5 mL); to this, 
potassium carbonate (100 mg) was added and the mixture 
stirred at 45 °C for 6 h, then diluted with petrol/EtOAc 
(1:1, 10 mL) and water (1 mL) and acidified with 
potassium hydrogen sulfate to pH 2. The aqueous layer was 
re-extracted with petrol/EtOAc (1:1, 2 × 10 mL), and the 
combined organic layers dried and the solvent evaporated. 
Chromatography (petrol/EtOAc, 20:1) gave a colourless 
oil, (2R,3R,21R,39R, 40R,E)-3-((tert-butyl-
dimethylsilyl)oxy)-2-docosyl-21,40-dimethyl-39-((tetra-
hydro-2H-pyran-2-yl)oxy)octapenta-cont-22-enoic acid (34 
mg, 70%),	[]
+1.58 (c 0.436 µmol, CHCl3) [MALDI-
Found (M+Na)+: 1432.3; C93H184NaO5Si requires: 1432.3]; 
δH (500 MHz, CDCl3): 5.34 (1H, dt, J 6.6, 15.1 Hz), 5.24 
(1H, dd, J 7.6, 15.1 Hz), 4.67 (0.5H, br t, J 3.0 Hz), 4.44 
(0.5H, br t, J 3.8 Hz), 3.97 – 3.89 (1H, m), 3.71 (1H, br q, J 
6.7 Hz), 3.57 – 3.42 (2H, m), 2.55 – 2.51 (1H, m), 2.05 – 
2.03 (1H, m), 1.97 (2H, q, J 7.0 Hz), 1.88 – 1.82 (1H, m), 
1.70 – 1. 31 (145H, br m including br s at 1.26), 0.94 (3H, 
d, J 7.0 Hz), 0.93 (9H, s), 0.89 (6H, t, J 6.6 Hz), 0.84 (3H, 
d, J 7.0 Hz), 0.15 (3H, s), 0.14 (3H, s); δC (126 MHz, 
CDCl3): 177.4, 136.6, 128.3, 98.5, 75.3, 73.7, 67.4, 49.9, 
41.7, 39.7, 37.6, 36.7, 35.8, 34.8, 33.3, 32.6, 31.9, 31.6, 
30.1, 30.0, 29.82, 29.8, 29.73, 29.7, 29.61, 29.6, 29.52, 
29.5, 29.42, 29.4, 29.1, 29.0, 27.7, 27.41, 27.4, 26.3, 25.8, 
25.7, 25.2, 22.73, 22.69, 22.6, 21.1, 20.9, 20.4, 19.4, 18.8, 
17.8, 14.3, 14.1, 13.6, 11.4, –4.3, –4.9; υmax: 3425, 2924, 
2853, 2362, 1702, 1464 cm-1.  
(iii) PPTS (29.6 mg, 0.118 mmol) was added to a stirred 
solution of the above  acid (17.3 mg, 0.0118 mmol) in THF 
(1 mL), methanol (0.1 mL) and water (0.1 mL) and the 
mixture refluxed for 2.5 h followed by stirring at 47 °C for 
24 h, then sat. aq. NaHCO3 (0.2 mL) was added and the 
product extracted with petrol/EtOAc (1:1, 3 × 5 mL). The 
combined organic layers were evaporated to give an oil; 
chromatography eluting with petrol/EtOAc (10:1) gave a 
colourless oil, (2R,3R,21R,39R,40R,E)-3-((tert-butyldi-
methylsilyl)-oxy)-2-docosyl-39-hydroxy-21,40-dimethyl-
octapentacont-22-enoic acid (12 mg, 73%), 	[]
+1.46 (c 
1.43 µmol, CHCl3) [MALDI-Found (M+Na)
+: 1348.5; 
C88H176NaO4Si requires: 1348.3]; δH (500 MHz, CDCl3): 
5.31 (1H, dt, J 6.6, 15.3 Hz), 5.24 (1H, dd, J 7.6, 15.3 Hz), 
3.83 (1H, dist. pent, J 2.3 Hz), 3.52 – 3.49 (1H, m), 2.55 –
2.51 (1H, m), 2.05 – 2.03 (1H, m), 1.97 (2H, q, J 6.6 Hz), 
1.63 – 1.22 (141H, br m including br s at 1.26), 0.97 (3H, 
d, J 6.7 Hz), 0.93 (9H, s), 0.89 (3H, d, J 7.3 Hz), 0.88 (6H, 
t, J 6.6 Hz), 0.15 (3H, s), 0.14 (3H, s); δC (126 MHz, 













  10 
37.3, 36.7, 35.8, 34.5, 33.4, 32.6, 31.9, 31.6, 30.1, 30.0, 
29.82, 29.8, 29.73, 29.7, 29.64, 29.6, 29.52, 29.5, 29.44, 
29.4, 29.1, 29.0, 27.7, 27.4, 27.37, 26.3, 25.8, 25.7, 25.2, 
22.72, 22.7, 22.6, 21.1, 20.9, 20.4, 19.4, 18.8, 17.9, 14.3, 
14.2, 14.1, 13.6, 11.4, –4.2, –4.9; υmax: 3424, 2923, 2852, 
1709, 1464 cm-1. 
(iv) The above acid (18.1 mg, 0.0131 mmol), in CH2 l2 (1 
mL) was added to a stirred suspension of PCC (8.47 mg, 
0.0393 mmol, 3 mol. equiv.) in CH2Cl2 (2 mL) at RT. The 
mixture was stirred for 1 h. The solvent was evaported; 
chromatography (petrol/EtOAc, 5:1) gave a white solid, 
(2R, 3R,21R,40R,E)-3-((tert-butyldimethylsilyl)oxy)-2-
docosyl-21,40-dimethyl-39-oxooctapentacont-22-enoic 
acid (16.0 mg, 89%), 	[]
+3.70 (c 0.457 µmol, CHCl3) 
[MALDI-Found (M+Na)+: 1346.4; C88H174NaO4Si 
requires: 1346.3]; δH (500 MHz, CDCl3): 5.33 (1H, dt, J 
6.0, 15.3 Hz), 5.24 (1H, dd, J 7.6, 15.3 Hz), 3.85 (1H, m), 
2.56 – 2.52 (1H, m), 2.50 (1H, br q, J 6.9 Hz), 2.41 (2H, dt, 
J, 1.9, 7.3 Hz), 2.05 – 2.00 (1H, m), 1.97 (2H, q, J 6.6 Hz), 
1.75 – 1.68 (2H, m), 1.64 – 1.21 (135H, br m including br s 
at 1.26), 1.05 (3H, d, J 6.6 Hz), 0.95 (3H, d, J 7.0 Hz), 0.93 
(9H, s), 0.89 (6H, t, J 6.6 Hz), 0.15 (3H, s), 0.14 (3H, s); δC 
(126 MHz, CDCl3): 215.3, 178.0, 136.5, 128.4, 73.7, 50.0, 
46.3, 41.2, 37.3, 36.7, 35.8, 33.1, 32.6, 31.9, 29.8, 29.72, 
29.7, 29.64, 29.61, 29.6, 29.54, 29.5, 29.48, 29.46, 29.44, 
29.4, 29.3, 29.23, 29.2, 27.4, 27.32, 27.3, 25.7, 25.2, 23.7, 
22.7, 20.1, 17.9, 16.4, 14.1, –4.2, – 4.9; vmax: 3419, 2925, 
2854, 2360, 2341, 1711, 1464 cm-1. 
(v) A dry polyethylene vial equipped with a rubber s ptum, 
was charged with the above acid (15 mg, 0.011 mmol) in 
dry THF (1 mL) under nitrogen at 0 °C. Pyridine (0.1 mL) 
and HF-pyridine complex (0.05 mL, 0.03263 mmol, 3 mol. 
equiv.) were added and the mixture stirred for 18h at 43 °C, 
then neutralised by slowly pouring it into sat. aq.NaHCO3 
(3 mL) until no more carbon dioxide was liberated. The 
product was extracted with petrol/ether (1:1, 3 × 10 mL), 
and evaporated to give a solid. Chromatography (petrol/ 
EtOAc, 5:1) gave a white solid, (2R,3R,21R,40R,E)-2-
docosyl-3-hydroxy-21,40-dimethyl-39-oxooctapentacont-
22-enoic acid 25 (6.0 mg, 44%),	[]
+2.90 (c 0.471 µmol, 
CHCl3) [MALDI-Found (M+Na)
+: 1232.3; C82H160NaO4 
requires: 1233.1]; δH (500 MHz, CDCl3): 5.32 (1H, td, J 
6.7, 15.5 Hz), 5.24 (1H, dd, J 7.6, 15.5 Hz), 3.72 (1H, m), 
2.50 – 2.45 (2H, m), 2.42 (2H, dt, J 1.6, 7.0 Hz), 2.02 (1H, 
m), 1.97 (2H, q, J 7.0 Hz), 1.65 – 1.17 (138H, br m, 
including br s at 1.26), 1.05 (3H, d, J 7.0 Hz), 0.95 (3H, d, 
J 7.0 Hz), 0.89 (6H, t, J 7.0 Hz); δC  (126 MHz, CDCl3): 
215.5, 177.9, 136.5, 128.4, 72.2, 50.6, 46.4, 41.2, 37.3, 
36.7, 35.6, 33.1, 32.6, 31.9, 29.8, 29.7, 29.64, 29.6, 29.54, 
29.51, 29.5, 29.43, 29.4, 29.3, 29.1, 28.9, 27.4, 27.3, 25.7, 
23.7, 22.7, 22.6, 21.0, 19.4, 16.4, 14.1; υmax: 3420, 3019, 
2926, 2855, 1521, 1420, 1215 cm-1.  
 
3.7 (2R,3R,21R,39R,40R,E)-2-Docosyl-3,39-dihydroxy-
21,40-dimethyloctapentacont-22-enoic acid 20 (R = R’ = 
H) 
Lithium hydroxide monohydrate (12.0 mg, 0.355 mmol, 30 
mol. equiv.) was added with stirring to ester 19 (15.0 mg, 
0.0118 mmol) (see Supplementary Information) in THF (2 
mL), methanol (0.2 mL) and water (0.2 mL) at RT. The 
mixture was stirred at 43 °C for 18 h, cooled to RT, then 
acidified with hydrochloric acid (5 %, 2 mL) and the 
aqueous layer extracted with warm petrol/ether (1:1, 3 × 10 
mL). The combined organic extracts were evaporated; 
chromatography (petrol/EtOAc, 5:1) gave a white solid, 
(2R,3R,21R,39R,40R,E)-2-docosyl-3,39-dihydroxy-21,40-
dimethyloctapentacont-22-enoic acid (20, R = R’ = H) (8.6 
mg, 59%), [α]20D +1.67 (c 1.29 µmol, CHCl3,) [Found 
(M+Na)+: 1234.5; C82H162NaO4 requires: 1234.2]; δH (500 
MHz, CDCl3): 5.33 (1H, dt, J 6.6, 15.5 Hz), 5.23 (1H, dd, J 
7.6, 15.5 Hz), 3.70 – 3.69 (1H, m), 3.52 – 3.51 (1H, m), 
2.45 (1H, br pent, J 4.7 Hz), 2.05 – 2.00 (1H, m), 1.97 (2H, 
q, J 6.9 Hz), 1.79 – 1.71 (1H, m), 1.66 – 1.59 (2H, m),1.64 
– 1.23 (139H, br m, including br s at 1.26), 0.94 (3H, d, J 
6.6 Hz), 0.89 (6H, t, J 7.0 Hz), 0.86 (3H, d, J 7.3 Hz); δC 
(126 MHz, CDCl3): 177.3, 136.5, 128.5, 75.4, 72.2, 50.5, 
37.3, 36.7, 34.4, 33.4, 32.6, 31.9, 30.0, 29.7, 29.6, 29.52, 
29.5, 29.4, 29.1, 27.4, 22.7, 21.0, 16.6, 14.1; υmax: 3534, 




LiHMDS (87.70 mL, 92.96 mmol, 1.06 M) was added to a 
stirred solution of 2,2-dimethylpropionic acid 9-(2-phenyl-
2H-pentazol-1-sulfonyl)nonyl ester 26 (27.03 g, 61.97 
mmol)43 and (R)-3-((S)-aldehyde 8 (8.20 g, 47.6 mmol)39, 45-
47 in dry THF  (200 mL) at –10 oC under nitrogen, then 
allowed to reach r.t. and stirred for 2 h.   Petrol/ether (1:1, 
100 mL) and sat. aq. NH4Cl (100 mL) were added, the 
organic layer was separated and the aq. layer was extracted 
with petrol/ether (1:1, 2 × 100 mL). The combined organic 
layers were evaporated. Chromatography (petrol/ether, 
50:1) gave a colourless oil, (E/Z)(R)-12-((S)-2,2-dimethyl-
1,3-dioxolan-4-yl)tridec-9-en-1-yl pivaloate	14	g, 76% 
in ratio (2.5:1). Palladium 10 % on carbon (1 g) was stirred 
with the above alkenes (14 g, 36 mmol) in IMS (200 mL) 
under hydrogen for 2 h. The solution was filtered on a bed 
of celite and evaporated to give a colourless oil of the title 
compound 27 (13 g, 92%),[]
 +16.1 (c 1.14, CHCl3) 
[Found [M – CH3]
+: 369.2989, C22H41O4 requires: 
369.2989]; δH (400 MHz, CDCl3): 4.05 (2H, t, J 6.6 Hz), 
4.0 (1H, dd, J 6.3, 7.9 Hz), 3.87 (1H, br q, J 6.9 Hz), 3.60 
(1H, br t, J 7.9 Hz), 1.62 (2H, quintet, J 6.6 Hz,), 1.40 (3H, 
s), 1.35 (3H, s), 1.32 – 1.26 (18H, m), 1.18 (9H, s), 1.1 – 
1.05 (1H, m), 0.96 (3H, d, J 6.6 Hz).	δC (126 MHz, CDCl3) 
: 178.6, 108.5, 80.4, 67.8, 64.5, 38.7, 36.5, 32.7, 9.9, 29.7, 
29.6, 29.59, 29.54, 29.50, 29.2, 28.6, 27.2, 27.0, 26.6, 25.9, 
25.5, 15.6; υmax/cm





 (i) A solution of (R)-12-((S)-2,2-dimethyl-1,3-dioxolan-4-
yl)tridecyl pivaloate  27 (12.7 g, 33.1 mmol) in dry THF 
(100 mL) was added slowly to a stirred suspension of 
LiAlH 4 (1.88 g, 49.6 mmol) at –20 
oC  under nitrogen. The 
mixture was heated under reflux for 1h, then  quench d 
with sat. aq. Na2SO4 (10 mL) at –10 
oC, stirred until a white 
precipitate formed, then MgSO4 (20 g) was added. The 
precipitate was filtered through celite and washed with 
THF (2 × 50 mL). Column chromatography (5:1 petrol/ 
ether) gave a colourless oil, (R)-12-((S)-2,2-dimethyl-1,3-
dioxolan-4-yl)-tridecan-1-ol (8.0 g, 81%), []
 +19.3 (c 
0.95, CHCl3) [Found [M–CH3]
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requires: 285.2425]; δH (400 MHz, CDCl3): 3.84 (1H, dd, J 
6.2, 7.7 Hz), 3.77 (1H, br q, J  7.0 Hz), 3.50 (1H, br t,J 7.7 
Hz), 3.41 (2H, t, J 6.6 Hz,), 1.52 – 1.47 (1H, m), 1.45 (3H, 
s), 1.43 – 1.40 (1H, m), 1.36 (3H, s), 1.34 –1.15 (20H, m), 
1.01 (3H, d, J 6.9 Hz);	δC (126 MHz, CDCl3): 108.7, 80.6, 
68.2, 62.7, 37.0, 33.3, 33.2, 30.4, 30.2, 30.18, 30.15, 30.14, 
30.12, 30.0, 27.4, 27.0, 26.3, 25.9, 15.9; υmax/cm
-1: 3395, 
2926, 2853, 1466, 1377, 1266, 1205, 1155, 1058. 
(ii) Diethyl azodicarboxylate  (6.1, 35 mmol) in dry THF (2 
mL) was added to a stirred solution of 1-phenyl-1H-
tetrazole-5-thiol (6.20 g, 35.0 mmol), Ph3  (9.12 g, 35.0 
mmol) and (R)-12-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)tri-
decan-1-ol (8.00 g, 27.0 mmol)  in dry THF (50 mL) at 0 
oC. The mixture was vigorously stirred at r. t. for 16 h. The 
solvent was evaporated and the residue was diluted with 
petrol/EtOAc (10:1), refluxed for 0.5 h then filtered, 
washed with petrol/EtOAc and the filtrate evaporated. 
Chromatography (petrol/ether, 5:1) gave a white solid, 5-
(((R)-12-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)tridecyl)thio)-
1-phenyl-1H-tetrazole (10.0 g, 84%), []
	+13.6 (c 0.88, 
CHCl3) [Found [M–CH3]
+: 445.2635, C24H37N4O2S 
requires: 445.2637]; δH (500 MHz, CDCl3): 7.60 – 7.52 
(5H, m), 4.0 (1H, dd, J 6.3, 7.9 Hz), 3.87 (1H, br q, J 7.1 
Hz), 3.60 (1H, br t, J 7.6 Hz), 3.39 (2H, t, J 7.4 Hz,), 1.82 
(2H, quintet, J 7.3 Hz), 1.58 – 1.53 (1H, m), 1.46 – 1.41 
(2H, m), 1.40 (3H, s), 1.35 (3H, s), 1.33 – 1.25 (1H, m), 
1.11 – 1.04 (1H, m), 0.96 (3H, d,J 6.6 Hz); 	δC (126 MHz, 
CDCl3) : 154.5, 133.8, 130.0, 129.7, 123.8, 108.4, 80.4, 
67.8, 36.5, 33.3, 32.7, 29.8, 29.6, 29.59, 29.5, 29.1, 29.0, 
28.6, 27.0, 26.6, 25.5, 15.6; νmax/cm
-1: 2925, 2854, 1598, 
1501, 1464, 1380, 1245, 1161, 1065.  
(iii) A solution of ammonium molybdate (VI) tetrahydrate 
(13 g, 10 mmol) in 35 % H2O2 (40 mL) was cooled in an 
ice bath and added to the above tetrazole (10.3 g, 22.0
mmol)  in  THF (100 mL) and IMS (250 mL) at 10 oC and 
stirred at r.t for 2 h. A further solution of ammonium 
molybdate  (6.9 g, 5.6 mmol) in 35 % H2O2 (20 mL) was 
added and the mixture was stirred at r.t. for 18 h. T e 
mixture was poured into water (1.2 L) and extracted with 
CH2Cl2 (1 × 200 mL, 3 × 30 mL). The combined organic 
phases were washed with water (500 mL), dried and 
evaporated. Chromatography (petrol/ether, 5:1) gave  
white solid, the title compound 28 (9.2 g, 84%), []
 
+12.6 (c 1.01, CHCl3) [Found [M – CH3]
+: 477.2523, 
C24H37N4O4S requires: 477.2531]; δH (500 MHz, CDCl3): 
7.71 – 7.69 (2H, m), 7.65 – 7.59 (3H, m), 4.00 (1H, dd  J 
6.3, 7.9 Hz), 3.87 (1H, br q, J 7.0 Hz), 3.75 – 3.72 (2H, m), 
3.60 (1H, br t, J 7.9 Hz), 1.99 – 1.92 (2H, m), 1.53 – 1.47 
(2H, m), 1.41 (3H, s), 1.35 (3H, s), 1.32 – 1.26 (1H, m), 
1.11 – 1.04 (1H, m), 0.96 (3H, d, J 6.6 Hz);	δC (126 MHz, 
CDCl3): 153.5, 133.0, 131.4, 129.7, 125.0, 108.5, 80.4, 
67.8, 56.0, 36.5, 33.7, 29.8, 29.6, 29.58, 29.5, 29.4, 29.2, 
28.9, 28.1, 27.0, 26.6, 25.5, 21.9, 15.6; υmax/cm
-1: 3069, 
2917, 2854, 1594, 1498, 1473, 1356, 1259, 1209, 1150, 
1064.   
 
3.10 Methyl (R)-2-((1R,15R)-1-((tert-butyldimethylsilyl)- 
oxy)-15-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)hexadecyl)- 
hexacosanoate 30 
LiHMDS (9.3 mL, 9.9 mmol, 1.06 M) was added to a 
stirred solution of sulfone 28 (3.23 g, 6.57 mmol) and  ester 
29 (3.27 g, 5.49 mmol)43 in dry THF  (50 mL) at –10 oC 
under nitrogen. The mixture was allowed to reach r. t., 
stirred for 2 h, then quenched with sat. aq. NH4Cl (100 mL) 
and diluted with petrol/ether (100 mL). The organic phase 
was separated and the aqueous layer was extracted wi h 
petrol/ether (1:1, 2 × 100 mL). The combined organic 
layers were dried and tevaporated. Chromatography (15:1 
petrol/ether) gave a colourless oil, methyl (E/Z)-(2R)-2-
((1R,15R)-1-((tert-butyldimethylsilyl)oxy)-15-(2,2-di-
methyl-1,3-dioxolan-4-yl)hexadec-3-en-1-yl)hexacosan-
oate	4.5	g, 96%	as	a	2.5: 1	mixture. Palladium (10% on 
carbon, 1.0 g) was added to the above alkenes (4.5 g, 5.21 
mmol) in EtOAc (150 mL) under hydrogen and stirred for 
1.5 h. The solution was filtered over celite and evaporated. 
Chromatography (petrol/ether, 15:1) gave a colourless oil, 
the title compound 30 (4.3 g, 96%), [α] 22
D
+3.6 (c 0.94, 
CHCl3) [Found [M+Na]
+: 887.7857, C54H108NaO5Si 
requires: 887.7863]; δH: 4.0 (1H, dd, J 6.3, 7.9 Hz), 3.93 – 
3.90 (1H, m), 3.87 (1H, br q, J 7.0 Hz), 3.66 (3H, s), 3.61 
(1H, br t, J 7.9 Hz), 2.53 (1H, ddd, J 3.8, 7.3, 11.1 Hz), 
1.59 –1.52 (4H, m), 1.41 (3H, s), 1.36 (3H, s), 1.35-1.26 
(68H, m, v. br), 1.10 – 1.07 (1H, m), 0.97 (3H, d, J 6.6 Hz), 
0.89 (3H, t, J 6.9 Hz), 0.87 (9H, s), 0.05 (3H, s), 0.03 (3H, 
s);	δC (126 MHz, CDCl3): 175.1, 108.5, 80.4, 73.2, 76.8, 
51.6, 51.2, 36.5, 33.7, 32.7, 31.9, 29.9, 29.8, 29.7, 29.66, 
29.62, 29.60, 29.58, 29.5, 29.4, 29.3, 27.8, 27.5, 27.0, 26.6, 
25.7, 25.5, 23.7, 22.7, 18.0, 15.6, 14.1, –4.4, –4.9; νmax/cm
-
1: 2925, 2854, 1741, 1465, 1368, 1253, 1165, 1068. 
 
3.11 Methyl (R)-2-((1R,15R)-1-((tert-butyldimethylsilyl)- 
oxy)-15-methyl-16-oxohexadecyl)hexacosanoate 31 
Periodic acid (0.40 g, 1.7 mmol) was added to a stirred 
solution of ester 30 (0.50 g, 0.58 mmol) in dry ether (35 
mL) at r.t. under nitrogen and stirred 18 h. The mixture was 
filtered through celite and washed with ether (20 mL). The 
solvent was evaporated and the product was purified by 
column chromatography eluting with petrol/EtOAc (5:1) to 
give a white solid, the title compound 31 (0.4 g, 87%) 
[Found [M–tBu]+: 735.6679; C46H91O4Si requires: 
735.6687];	δH (500 MHz, CDCl3): 9.77 (1H, t, J 1.9 Hz), 
5.11 – 5.07 (1H, m), 3.92 – 3.89 (1H, m), 3.66 (3H, s), 2.52 
(1H, ddd, J 3.8, 7.0, 11.0 Hz), 2.42 (2H, dt, J 1.9, 7.6 Hz), 
1.63 (2H, pent, J 6.3 Hz), 1.55 – 1.22 (68H, m), 1.09 (3H, 
d, J 7.0 Hz), 0.88 (3H, t, J 7 Hz), 0.87 (9H, s), 0.05 (3H, s), 
0.027 (3H, s); δC (126 MHz, CDCl3): 202.8, 175.1, 73.2, 
51.6, 51.2, 43.9, 33.7, 31.9, 29.8, 29.7, 29.65, 29.6, 29.5, 
29.4, 29.35, 29.3, 29.2, 27.9, 27.5, 25.8, 23.8, 22.7, 2.1, 
18.0,14.1, –4.4, –4.9; νmax/cm




LiHMDS (1.1 mL, 1.0 mmol, 1.06 M) was added dropwise 
to a stirred solution of (8S, 9S)-8-methoxy-9-methyl-
heptacosanal 32 (0.34 g, 0.77 mmol)39 and 2,2-dimethyl-
propionic acid 13-(1-phenyl-1H-tetrazole-5-sulfonyl)-
tridecyl ester 7 (0.42 g, 0.93 mmol) in dry THF (15 mL ) 
under nitrogen at –15 oC. The solution was allowed to 
reach r.t. and stirred for 2 h. Work up as in 3.10 and 
chromatography (petrol/EtOAc, 20:1) gave a colourless oil, 
(21S,22S,E)-21-methoxy-22-methyltetracont-13-en-1-yl 
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carbon (0.5 g) was added to a stirred solution of the alkene 
(0.46 g, 0.65 mmol) in IMS (15 mL) and THF (5 mL) 
under hydrogen. Hydrogenation was carried out for 1 h. 
The mixture was filtered over celite and the solvent was 
evaporated. Chromatography eluting with petrol/EtOAc 
(20:1) to give a colourless oil,  of the title compound 33 
(0.46g, 100 %), []
 –6.5 (c 1.50, CHCl3) [Found 
[M+Na]+: 729.7102, C47H94NaO3 requires: 729.7100]; δH: 
(500 MHz, CDCl3): 4.05 (2H, t, J 6.7 Hz), 3.34 (3H, s), 
2.97 – 2.94 (1H, m), 1.62 (2H, pent, J 6.7 Hz), 1.46 – 1.22 
(70H, m), 1.20 (9H, s), 1.12 – 1.06 (1H, m), 0.88 (3H, t, J 
6.7 Hz), 0.85 (3H, d, J 7.0 Hz); δC (126 MHz, CDCl3): 
178.5, 85.4, 64.4, 57.7, 38.7, 35.3, 32.4, 31.9, 30.8, 30.5, 
30.0, 29.9, 29.7, 29.69, 29.66, 29.6, 29.5, 29.4, 29.2, 28.6, 






(i) A solution of pivaloate 33 (0.75 g, 1.06 mmol) in HPLC 
grad THF (15 mL) was added to a stirred solution of LAH 
(0.2 g, 1.6 mmol) in THF (35 mL) at –20 oC under argon. 
The mixture was allowed to warm and refluxed for 1h, then 
sat. aq. sodium sulfate was added at –20 oC until a white 
precipitate had formed and THF (20  mL) was added. The
mixture was stirred at r.t. for 30 min, filtered through celite 
and evaporated. Chromatography (petrol/EtOAc, 10:1 then 
5:1) gave a white solid, (21S,22S)-21-methoxy-22-methyl-
tetracontan-1-ol  (0.65 g, 99 %), mp. 46 – 48 oC, []
 –
8.21 (c 1.21, CHCl3) [Found [M–H]
+: 621.6545, C42H85O2 
requires: 621.6549]; δH: (500 MHz, CDCl3): 3.66 (2H, t, J 
6.6 Hz), 3.36 (3H, s), 2.99 – 2.96 (1H, m), 1.67 – 1.64 (1H, 
m), 1.59 (2H, pent, J 6.6 Hz), 1.49 (1H, br s), 1.48 – 1.22 
(69H, m), 1.14 – 1.07 (1H, m), 0.90 (3H, t, J 7.0 Hz), 0.87 
(3H, d, J 6.7 Hz); δC (126 MHz, CDCl3): 85.5, 63.1, 57.7, 
35.3, 32.8, 32.4, 31.9, 30.5, 30.0, 29.9, 29.7, 29.68, 29.63, 
29.5, 29.4, 27.6, 26.2, 25.7, 22.7, 14.9, 14.1; νmax/cm
-1: 
3373, 2921, 1098,1076. 
(ii) DEAD (0.27 g, 1.6 mmol) in dry THF (2 mL) was 
added to a stirred solution of 1-phenyl-1H tetrazole-5-thiol 
(0.28 g, 1.6 mmol), Ph3P (0.41 g, 1.6 mmol) and  the above 
alcohol  (0.75 g, 1.2 mmol)  in dry THF (25 mL) at 0 oC, 
The mixture was vigorously stirred and refluxed for 2.5 h, 
then 5:1 petroleum/EtOAc (100 mL) was added. The 
mixture filtered through celite and the solvent was 
evaporated. Chroma-tography (petrol/ether, 5:1) gave  
white solid, 5-(((21S, 22S)-21-methoxy-22-
methyltetracontyl)thio)-1-methyl-1H-tetrazole (0.80 g, 
91%),	[]
 –6.4 (c 1.2, CHCl3) [MALDI–Found (M+Na)
+: 
805.3, C49H90NaN4OS requires: 805.6]; δH: (500 MHz, 
CDCl3): 7.65 – 7.61 (5H, m), 3.66 (2H, t, J 6.3 Hz), 3.36 
(3H, s), 2.98 – 2.96 (1H, m), 1.97 (2H, br pent, J 7.5 Hz), 
1.68 – 1.61 (2H, m), 1.52 (2H, br pent, J 7.5 Hz), 1.45 – 
1.22 (66H, m), 1.15 – 1.07 (1H, m), 0.90 (3H, t, J 6.6 Hz), 
0.87 (3H, d, J 6.9 Hz); δC: (126 MHz, CDCl3): 153.5, 
133.1, 131.5, 129.7, 125.1, 85.5, 57.7, 56.0, 35.3, 32.4, 
31.9, 30.5, 30.0, 29.97, 29.7, 29.65, 29.6, 29.5, 29.4, 29.2, 
28.9, 28.2, 27.6, 26.2, 22.7, 21.9, 14.9, 14.1; νmax/cm
-1: 
3072, 2917, 2853, 1343, 1096. 
(iii) To a stirred solution of the above tetrazole (0.80 g, 1.0 
mmol) and NaHCO3 (0.34, 4.1 mmol) in CH2Cl2 (50 mL) 
was added m-chloroperbenzoic acid (0.41 g, 2.35 mmol) at 
r.t. and stirred for 24 h. The mixture was quenched with 
10% NaOH solution (25 mL) and vigorously stirred for 2 h. 
The organic layer was separated and the aqueous layer was 
extracted with CH2Cl2 (2 × 50 mL). The combined organic 
layers were washed with water, dried and evaporated. 
Chromatography (petroleum/ether, 10:1) gave a white 
solid, sulfone 34 (0.81 g, 97%), mp.: 44 – 46 oC; 	[]
 –
6.19 (c 1.39, CHCl3) [MALDI–Found: [M+Na]
+: 837.3, 
C49H90N4NaO3S requires: 837.6]; δH (500 MHz, CDCl3): 
7.73 – 7.71 (2H, m), 7.65 – 7.61 (3H, m), 3.75 (2H, 
distorted t, J 7.9 Hz), 3.36 (3H, s), 2.98 – 2.96 (1H, m), 
1.97 (2H, br pent, J 7.5 Hz), 1.68 –1.61 (2H, m), 1.52 (2H, 
br pent, J 7.5 Hz), 1.45 – 1.22 (66H, m), 1.15 – 1.07 (1H, 
m), 0.90 (3H, t, J 6.6 Hz), 0.87 (3H, d, J 6.9 Hz); δC (126 
MHz, CDCl3): 153.5, 133.1, 131.5, 129.7, 125.1, 85.5, 
57.7, 56.0, 35.3, 32.4, 31.9, 30.5, 30.0, 29.9, 29.7, 29.65, 
29.6, 29.5, 29.4, 29.2, 28.9, 28.2, 27.6, 26.2, 22.7, 1.9, 




40-dimethyl-2-tetracosyloctapentacont-18-enoic acid 37 
(i) Ester 31 (0.30 g, 0.38 mmol) in dry 1,2-
dimethoxyethane (60 mL) was added to stirred solution of 
sulfone 34 (0.34 g, 0.42 mmol) in dry 1,2-dimethoxyethane 
(25 mL) under nitrogen at RT. The mixture was cooled to –
20 oC and potassium bis (trimethylsilyl)amide (1.08 mL, 
0.42 mmol, 0.5 M in toluene) was added and the mixture 
allowed to reach r.t. and then stirred for 1.5 h. Sat. aq. 
NH4Cl (30 mL) and petrol /ether (1:1, 55 mL) were added. 
The aqueous layer was extracted with petrol/ether (1:1, 2 × 
45 mL). The combined organic layers were evaporated. 
Chromatography (petrol/ether, 18:1) gave a semi solid, 
methyl (2R,3R,17R, 39S,40S,E)-3-((tert-
butyldimethylsilyl)oxy)-39-methoxy-17,40-dimethyl-2-
tetracosyloctapentacont-18-enoate 35 (0.18 g, 37%) 
[MALDI–Found [M+Na]+: 1404.3; C92H184NaO4Si 
requires: 1404.3]; δH: 5.33 (1H, dt, J 6.36, 15.0 Hz), 5.24 
(1H, dd, J 7.4, 15.0 Hz), 3.9 (1H, td, J 4.3, 6.8 Hz), 3.65 
(3H, s),  3.35 (3H, s), 2.98 – 2.94 (1H, m), 2.53 (1H, ddd, J 
3.7, 7.0, 10.8 Hz), 2.05 – 2.0 (1H, m),  1.97 (2H, q, J 6.9 
Hz), 1.68 – 1.26 (142H, m, v.br), 1.08 – 1.01 (1H, m) 0.94 
(3H, d, J 7.0 Hz), 0.90 (6H, t, J 6.7 Hz), 0.87 (9H, s), 0.85 
(3H, d, J 7.0 Hz), 0.52 (3H, s), 0.03 (3H, s); δC: (101 MHz, 
CDCl3): 175.2, 136.5, 128.4, 85.4, 73.2, 57.7, 51.6, 51.2, 
37.3, 36.7, 35.3, 33.7, 32.6, 32.4, 31.9, 30.5, 30.0, 29.9, 
29.84, 29.8, 29.7, 29.66, 29.6, 29.5, 29.45, 29.4, 29.1, 27.8, 
27.6, 27.5, 27.4, 26.2, 25.8, 23.7, 22.7, 20.9, 14.9, 14.1, –
4.4, –4.9; vmax/cm
-1: 2924, 2854, 1741, 1465, 1377, 1254, 
1099. 
(ii) The ester 35 (0.70 mg, 0.05 mmol) was dissolved in dry 
THF (10 mL) in a dry polyethylene vial under nitrogen at 
r.t. and stirred. Pyridine (0.07 mL) and HF–pyridine 
complex (0.5 mL) were added; the mixture was stirred for 
17 h. at 42 °C, neutralized with sat. aq. NaHCO3, then 
extracted with petrol/EtOAc (1:5, 3 × 50 mL). The 
combined organic layers were washed with brine, dried and 
evaporated; chromatography (petrol/EtOAc, 20:1) gave  
white solid, methyl (2R,3R,17R,39S, 40S,E)-3-hydroxy-39-
methoxy-17,40-dimethyl-2-tetracosyloctapentacont-18-en-
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[M+Na]+: 1290.3; C86H170NaO4 requires: 1290.2]; δH: 5.33 
(1H, dt, J 6.4, 15.0 Hz), 5.24 (1H, dd, J 7.5, 15.0 Hz), 3.72  
(3H, s), 3.68 – 3.63 (1H, m), 3.35 (3H, s), 2.98 – 2.93 (1H, 
m), 2.46 – 2.41 (1H, td, J 5.4, 9.1 Hz), 2.05 – 2.0 (1H, m), 
1.97 (2H, br q, J 7 Hz), 1.76 – 1.68 (1H, m), 1.65 – 1.5 
(12H, m), 1.48 – 1.2 (128H, m), 1.15 – 1.05 (1H, m)0.95 
(3H, d, J 6.7 Hz), 0.89 (6 H, t, J 7.1 Hz), 0.86 (3H, d, J 6.8 
Hz), 1.96 (2H, br q, J 7 Hz); δC (101 MHz, CDCl3): 176.2, 
136.5, 128.4, 85.4, 72.3, 57.7, 51.5, 50.9, 37.2, 36.7, 35.7, 
35.3, 32.6, 32.4, 31.9, 30.5, 30.0, 29.9, 29.8, 29.7, 29.6, 
29.56, 29.5, 29.4, 29.36, 29.1, 27.6, 27.4, 27.36, 26.2, 25.7, 
22.7, 20.9, 14.9, 14.1; νmax/cm
-1: 3431, 2917, 2850, 1739, 
1466, 1099. 
(iii) Lithium hydroxide monohydrate (0.31 g, 7.3 mmol) 
was added with stirring to ester 36 (0.62 g, 0.49 mmol) in 
THF (15 mL), methanol (1.3 mL) and water (1.5 mL) at r. 
t. The mixture was stirred at 43 oC for 18 h. The mixture 
was cooled to r.t. and acidified with HCl (5%, 2 mL) and 
the aqueous layer was extracted with warm petroleum/ ther 
(1:1, 3 × 50 mL). The combined organic layers were dri d 
and evaporated; chromatography (warm petroleum/EtOAc, 
7:2) gave a white solid, compound 37 (0.50, 82%), m.p.: 43 
– 45 oC [MALDI–Found [M+Na]+: 1276.2861; 
C85H168NaO4 requires: 1276.2835]; δH (500 MHz, CDCl3): 
5.33 (1H, dt, J 6.4, 15.2 Hz), 5.24 (1H, dd, J 7.4, 15.2 Hz), 
3.73 – 3.70 (1H, m),  3.35 (3H, s), 2.98 – 2.96 (1H, m), 
2.49 – 2.44 (1H, m), 2.0 –1.97 (1H, m), 1.96 (2H, br q, J 
6.7 Hz), 1.77 – 1.70 (1H, m), 1.67 – 1.57 (2H, m), 1.55 – 
1.15 (141 H, m), 1.14 – 1.05 (1H, m), 0.94 (3H, d, J 6.7 
Hz), 0.89 (6H, t, J 6.5 Hz), 0.85 (3H, d, J 6.9 Hz); δC (101 
MHz, CDCl3): 179.5, 136.5, 128.4, 85.6, 72.1, 57.7, 50.7, 
37.3, 36.7, 35.6, 35.3, 32.6, 32.4, 31.9, 30.5, 29.9, 29.7, 
29.5, 29.4, 29.36, 29.1,  27.6, 27.4, 22.4, 21.0, 14.9, 14.1; 
νmax/cm
-1: 3470, 2917, 2854, 1726, 1689, 1471, 1392, 1202, 




20-enoic acid 44 
Imidazole (0.125 g, 1.80 mmol) was added to a stirred 
solution of acid 37 (0.23 g, 0.18 mmol) in dry DMF (1.5 
mL) and dry toluene (2.5 mL) at r. t. followed by the 
addition of TBDMSCl (0.27 g, 1.8 mmol) and DMAP (10 
mg). The mixture was stirred at 70 oC for 24 h. The solvent 
was evaporated under reduced pressure and the residue was 
diluted with EtOAc (50 mL) and water (20 mL). The 
organic layer was separated and the aqueous layer was 
extracted with EtOAc (2 × 30 mL). The combined organic 
layers were washed with water, dried and evaporated to 
give a colourless oil. The residue was dissolved in THF (8 
mL) and n-Bu4NOH (0.9 mL, 4%) and stirred for 10 min. at 
r. t. then diluted with water (10 mL) and extracted with 
EtOAc (2 × 20 mL), dried and evaporated to give a rsidue; 
column chromatography (petroleum/EtOAc, 20:1) gave  
colourless oil, the title compound 44 (0.25 g, 96%) 
[MALDI–Found [M+Na]+: 1390.3; C91H182NaO4Si 
requires: 1390.3]; δH (500 MHz, CDCl3): 5.33 (1H, dt, J 
6.4, 15.0 Hz), 5.25 (1H, dd, J 7.5, 15.0 Hz), 3.86 – 3.80 
(1H, m),  3.35 (3H, s), 2.99 – 2.94 (1H, m), 2.57 – 2.51 
(1H, m), 2.07 – 2.01 (1H, m), 1.96 (2H, br q, J 6.8 Hz), 
1.73 – 1.68 (1H, m), 1.65 –1.54 (4H, m), 1.5 – 1.2 ( 38H, 
m), 1.1 – 1.0 (1H, m), 0.95 (3H, s), 0.94 (9H, s), 0.89 (6H, 
t, J 6.7 Hz), 0.85 (3H, d, J 6.9 Hz), 0.16 (3H, s), 0.14 (3H, 
s); δC (101 MHz, CDCl3): 174.9, 136.5, 128.4, 85.5, 73.7, 
57.7, 50.0, 37.3, 36.7, 35.8, 35.3, 32.6, 32.4, 31.9, 30.5, 
30.1, 30.0, 29.9, 29.8, 29.7, 29.63, 29.6, 29.54, 29.5, 29.4, 
29.36, 29.1, 27.6, 27.4, 27.36, 26.2, 25.9, 25.7, 25.5, 25.1, 
22.7, 20.9, 17.9, 14.9, 14.1, –4.3, –4.9; νmax: 2922, 2852, 





(trimethylsilyl)- α,α’-trehalose 46 and 6-O-(2R,3R,17R, 
39S,40S,E)-3-((tert-butyldimethylsilyl)oxy)-39-methoxy-
17,40-dimethyl-2-tetracosylocta-pentacont-18-enoic-2,3, 
4,2’,3’,4’-hexakis-O-(trimethylsilyl)- α,α’-trehalose 47 
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimidehydro- 
chloride (EDCI) (0.044 g, 0.230 mmol) and DMAP (0.028 
g, 0.23 mmol) were added to a stirred solution of acid 44 
(0.090 g, 0.065 mmol),  protected α,α᾽-trehalose 45  (0.022 
g, 0.028 mmol)67 and powdered 4 Ǻ molecular sieve in dry 
CH2Cl2 (1 mL) at r. t. under nitrogen. The mixture was 
stirred for 6 days, diluted with CH2Cl2 (3 mL) and silica (5 
g), then the solvent was evaporated. Chromatography 
(petroleum/EtOAc, 20:1) gave a first fraction, the TDM 46 
(0.228 g, 25%), []
	 +19 (c 1.2, CHCl3) [MALDI–Found 
[M+Na]+: 3496.4; C212H430NaO17Si8 requires: 3496.0]; δH 
(400 MHz, CDCl3): 5.35 (2H, dt, J 6.4, 15.3 Hz), 5.25 (2H, 
br dd, J 7.4, 15.3 Hz), 4.85 (2H, br d, J 3.0 Hz), 4.36 (2H, 
br d, J 10.8 Hz), 4.01 (2H, br tt, J 3.1, 10.8 Hz), 3.94 (2H, 
br pent, J 5.1 Hz), 3.9 (2H, br t, J 8.8 Hz), 3.52 (2H, br t, J
9.0 Hz), 3.38 (2H, dd, J 2.9, 9.3 Hz), 3.34 (6H, s), 2.96 
(2H, br pent, J 4.2 Hz), 2.57 – 2.53 (2H, m), 2.03 (2H, br 
pent, J 6.5 Hz), 1.96 (4H, br q, J 6.7 Hz), 1.7 – 1.2  (292H, 
m), 1.13 – 1.07 (2H, m), 0.9 (6H, d, J 6.7 Hz), 0.89 (12H, t, 
J 6.6 Hz), 0.88 (18H, s), 0.16 (18H, s), 0.15  (18H, s), 0.14 
(18H, s), 0.06 (12H, s); δC (101 MHz, CDCl3): 173.8, 
136.5, 128.4, 94.8, 85.4, 73.5, 73.4, 72.8, 71.8, 70.7, 62.4, 
57.7, 51.9, 37.3, 36.7, 35.3, 32.6, 32.4, 31.9, 30.5, 30.0, 
29.95, 29.9, 29.7, 29.66, 29.6, 29.5, 29.4, 29.2, 27.6, 27.4, 
26.2, 25.8, 22.7, 20.9, 18.0, 14.9, 14.1, 1.1, 0.9, .2, –4.5, –
4.7; νmax: 2924, 2853, 1743, 1466, 1377, 1251, 1163, 1100 
cm-1.  The second fraction was TMM 47 (0.072 g, 50%), 
[]
	+32 (c 1.1, CHCl3) [MALDI–Found [M+Na]
+: 
2146.7; C121H250NaO14Si7 requires: 2146.7]; δH (500 MHz, 
CDCl3): 5.34 (1H, dt, J 6.4, 15.3 Hz), 5.24 (1H, dd, J 7.4, 
15.3 Hz), 4.91 (1H, d, J 3.0 Hz), 4.84 (1H, d, J 3.0 Hz), 
4.35 (1H, dd, J 2.0, 11.8 Hz), 4.08 (1H, dd, J 4.1, 11.8 Hz), 
4.0 (1H, td, J 2.2, 9.5 Hz), 3.96 – 3.92 (2H, m), 3.89 (1H, 
dd, J 5.2, 8.9 Hz), 3.84 (1H, td, J 3.0, 9.4 Hz), 3.73 – 3.64 
(2H, m), 3.5 (1H, dd, J 3.7, 9.0 Hz), 3.49 (1H, dd, J 3.7, 9.0 
Hz), 3.47 (1H, dd, J 3.7, 9.0 Hz), 3.43 (1H, dd, J 3.0, 9.3 
Hz), 3.4 (1H, dd, J 3.0, 9.3 Hz), 3.35 (3H, s), 2.96 (1H, br 
pent, J 4.2 Hz), 2.56 (1H, ddd, J 3.36, 5.4, 9.7 Hz), 2.1 – 
2.0 (1H, m), 1.96 (2H, br q, J 6.7 Hz), 1.72  (1H, br t, J 5.2, 
6.9 Hz), 1.67 – 1.57 (3H, m), 1.5 – 1.15 (138H, m),1.3 – 
1.07 (1H, m), 0.94 (3H, d, J 6.7 Hz), 0.89 (6H, t, J 6.6 Hz), 
0.87 (9H, s), 0.85 (3H, d, J 7.0 Hz), 0.17 (9H, s), 0.16 (9H, 
s), 0.15 (9H, s), 0.148 (18H, s), 0.12 (9H, s), 0.06 (3H, s), 
0.055 (3H, s); δC (101 MHz, CDCl3): 174.1, 136.5, 128.4, 
94.5, 94.4, 85.4, 73.4, 73.3, 72.9, 72.8, 72.7, 72.0, 71.4, 
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32.3, 31.9, 30.5, 30.0, 29.9, 29.8, 29.7, 29.66, 29.5, 29.4, 
29.2, 28.1, 27.6, 27.4, 26.4, 26.2, 25.8, 24.8, 22.7, 0.9, 
18.0, 14.9, 14.1, 1.1, 1.0, 0.9, 0.85, 0.2, 0.04, –4.5, –4.7; 






(i) n-Bu4NF (0.1 mL, 0.1 mmol, 1 M) was added to a 
stirred solution of diester 46 (0.06 g, 0.017 mmol) in dry 
THF (5 mL) at 5 oC under nitrogen, allowed to reach r.t., 
stirred for 1 h, then evaporated under reduced pressu . 
Chroma-tography (CHCl3/MeOH, 10:1) gave 6,6’-bis-O-
(2R,3R,17R, 39S,40S,E)-3-((tert-butyldimethylsilyl)oxy)-
39-methoxy-17,40-dimethyl-2-tetracosyloctapentacont-18-
enoic-α,α’-trehalose 48 (0.035 g, 67%), [] +19.5 (c 
0.50, CHCl3) [MALDI–Found [M+Na]
+: 3063.9; 
C194H382NaO17Si2 requires: 3063.8]; δH (500 MHz, CDCl3 + 
few drops of CD3OD): 5.27 (2H, dt, J 6.5, 15.3 Hz), 5.18 ( 
2H, dd,  J 7.4, 15.3 Hz), 5.04 (2H, d, J 3.4 Hz), 4.3 (2H, br 
dd, J 3.8, 12.0 Hz), 4.2 (2H, br d, J 10.84 Hz), 3.91 (2H, br 
d, J 9.4 Hz), 3.85 (2H, br q, J 5.0 Hz), 3.76 (2H, br t, J 9.3 
Hz), 3.44 (2H, dd, J 3.4, 9.6 Hz), 3.32 (2H, br m), 3.3 (6H, 
s), 2.94 – 2.91 (2H, m), 2.53 – 2.48 (2H, m), 1.97 (2H, br 
pent, J 6.3 Hz), 1.91 (2H, br q, J 6.8 Hz), 1.57 – 1.1 (292H, 
m), 1.07 – 1.0 (2H, m), 0.88 (6H, d, J 6.7 Hz), 0.84 (12H, t, 
J 6.3 Hz), 0.81 (18H, s), 0.8 (6H, d, J 7.3 Hz), –0.003 (6H, 
s), –0.023 (6H, s);  δC (101 MHz, CDCl3 + CD3OD): 175.2, 
136.4, 128.3, 93.5, 85.5, 73.2, 73.1, 71.6, 70.2, 69.9, 62.9, 
57.6, 51.59, 37.1, 36.57, 35.2, 33.5, 32.5, 32.3, 31.8, 30.4, 
29.83, 29.8, 29.7, 29.63, 29.6, 29.57, 29.4, 29.2, 29.0, 27.7, 
27.4, 27.3, 26.9, 26.0, 25.7, 25.6, 24.1, 22.6, 20.8, 17.8, 
14.7, 13.9, –4.6, –5.0; νmax: 3400, 2924, 2853, 1742, 1464, 
1100 cm-1. 
(ii) A dry polyethylene vial equipped with a rubber septum 
was charged with 48 (0.022 g, 0.007 mmol) and pyridine 
(0.05 mL) in dry THF (1.3 mL) and stirred at r. t. under 
argon. To it was added hydrogen fluoride-pyridine complex 
(~70% HF, 0.2 mL). The mixture was stirred at 43 oC for 
17 h, then poured slowly into sat. aq. NaHCO3 until no 
more CO2 was liberated. The product was extracted with 
CHCl3 (3 × 50 mL); the combined organic layers were 
evaporated to give a residue. Chromatography 
(CHCl3/MeOH, 10:1) gave   compound 49 (0.015, 75%), 
[]
 +18 (c 1.0, CHCl3) [Found [M+Na]
+: 283.6751; 
C182H354NaO17 requires: 2835.6728]; δH (500 MHz, CDCl3 
+ few drops of CD3OD): 5.3 (2H, dt, J 6.2, 15.6 Hz), 5.21 
(2H, dd,  J 7.2, 15.6 Hz), 5.0 (2H, br d, J 3.4 Hz), 4.68 (2H, 
br d, J  11.9 Hz), 4.23 (2H, br t, J 9.4 Hz), 4.0 – 3.94 (2H, m), 
3.74 (2H, br t, J 9.3 Hz), 3.67 – 3.62 (2H, m), 3.5 (2H, dd, J 2.8, 
9.6 Hz), 3.32 (6H, s), 3.21 (2H, t, J 9.3 Hz), 2.96 – 2.93 (2H, m), 
2.4 (2H, m), 1.97 – 2.02 (2H, m), 1.93 (4H, br q, J 6.7 Hz), 1.65 – 
1.01 (294H, m), 0.91 (6H, d, J 6.7 Hz), 0.86 (12H, t , J 6.7 Hz), 
0.82 (6H, d, J 7 Hz);  δC (101 MHz, CDCl3 + few drops of  
CD3OD): 175.2, 136.2, 128.2, 94.0, 85.5, 72.8, 72.3, 71.3, 70.6, 
69.8, 63.5, 57.4, 52.4, 37.0, 36.5, 35.1, 34.6, 32.3, 32.1, 31.7, 
30.2, 29.7, 29.6, 29.6, 29.4, 29.3, 29.3, 29.2, 29.1, 29.0, 28.9, 
27.2, 27.1, 27.1, 25.8, 25.1, 22.4, 20.6, 14.5, 13.8; υmax 3584, 




enoic-α,α’-trehalose  51  
(i) n-Bu4NF (0.16 mL, 0.16 mmol, 1M) was added with 
stirring to monoester 47 (0.058 g, 0.027 mmol) in dry THF 
(2 mL) at 5 oC under nitrogen, stirred at r.t. for 1 h, then 
worked up and purified as before to give 6-O-(2R,3R,17R, 
39S,40S,E)-3-((tert-butyldimethylsilyl)oxy)-39-methoxy-
17,40-dimethyl-2-tetracosyloctapentacont-18-enoic-α,α’
trehalose 50 (0.030, 65%) as a colourless oil, []
 +39.5 
(c 0.75, CHCl3) [MALDI–Found [M+Na]
+: 1714.2; 
C103H202NaO14Si requires: 1714.4]; δH (500 MHz, CDCl3 + 
few drop of CD3OD): 5.28 (1H, dt, J 6.5, 15.5 Hz), 5.19 
(1H, br dd, J 7.6, 15.5 Hz), 5.05 (2H, br t, J 3.5 Hz), 4.3 
(1H, dd, J 4.6, 12.3 Hz), 4.23 (1H, dd, J 2.3, 12.3 Hz), 3.9 
(1H, br d, J 8.3 Hz), 3.87 – 3.84 (1H, m), 3.81 – 3.71 (4H, 
m), 3.65 (1H, dd, J 5.2, 11.6 Hz), 3.47 (1H, dd, J 3.9, 5.9 
Hz), 3.46 (1H, dd, J 5.9, 9.7 Hz), 3.3 (3H, s), 2.93 – 2.91 
(1H, m), 2.6 – 2.48 (1H, m), 1.99 – 1.95 (1H, m), 1.91 (2H, 
br q, J 7.0 Hz), 1.6 – 1.55 (1H, m), 1.45 – 1.15  ( 150H, m)
1.07 – 1.03 (1H, m), 0.89 (3H, d, J 6.7 Hz), 0.83 (6H, t, J
7.0 Hz), 0.81 (9H, s), 0.8 (3H, d, J 7.0 Hz), –0.003  (3H, s), 
–0.024 (3H, s); δC (101 MHz, CDCl3 + few drops of  
CD3OD): 174.9, 136.4, 128.3, 93.5, 93.4, 85.5, 73.2, 72.2, 
71.7, 70.7, 70.3, 70.0, 62.7, 62.0, 58.7, 57.6, 52.1, 51.7, 
50.1, 37.2, 36.6, 35.2, 32.5, 32.3, 31.8, 30.4, 29.8, 29.8, 
29.7, 29.7, 29.6, 29.5, 29.4, 29.2, 29.0, 27.4, 27.3, 26.0, 
25.7, 25.1, 23.8, 22.6, 20.8, 20.0, 19.6, 17.9, 14.7, 14.0, 
13.4, 13.38, –4.6, –5.0; υmax: 3903, 3368, 2918, 2850, 1733, 
1468, 1378, 1253, 1148, 1102, 1078, 1051, 992, 941,836  
775, 721 cm-1.  
 (ii) Compound  50 (0.025 g, 0.015 mmol) and pyridine 
(0.05 mL) in dry THF (3 mL) in a dry polyethylene vial 
equipped with a rubber septum was stirred at r. t. under 
argon, and hydrogen fluoride-pyridine complex (~70% HF, 
0.25 mL) was added. The mixture was stirred at 43 oC for 
17 h, then worked up and purified as above to give the title 
compound 51 (0.015, 65%), []
 +34 (c 0.52, CHCl3) 
[MALDI–Found [M+Na]+: 1600.3879; C97H188NaO14 
requires: 1600.3897]; δH (400 MHz, CDCl3): 5.26 (1H, dt, J 
6.6, 15.2 Hz), 5.17 (1H, br dd, J 7.4, 15.2 Hz), 5.03 (1H, d, 
J 3.2 Hz), 4.98 (1H, d, J 3.3 Hz), 4.61 (1H, br d, J 11 Hz), 
4.18 (1H, br t, J 7.9 Hz), 3.95 (1H, dd, J 7.8, 12.0 Hz), 3.87 
– 3.82 (1H, m), 3.79 – 3.71 (2H, m), 3.62 –3.55 (2H, m), 
3.5 (1H, dd, J 3.2, 9.8 Hz), 3.44 (1H, dd, J 3.3, 9.8 Hz), 
3.32 (8H, br s), 3.28 (3H, s), 3.23 (1H, br t, J 9.5 Hz), 3.18 
(1H, br t, J 9.6 Hz), 2.93 – 2.89 (1H, m), 2.38 –2.33 (1H, 
m), 1.99 – 1.94 (1H, m), 1.9 (2H, br q, J 6.8 Hz), 1.57 – 
1.10 (143H, m), 1.06 – 0.98 (1H, m), 0.87 (3H, d, J 6.7 
Hz), 0.81 (6H, t, J 6.4 Hz), 0.78 (3H, d, J 7.1 Hz); δC (101 
MHz, CDCl3): 175.4, 136.3, 128.3, 94.6, 85.5, 72.6, 72.4, 
72.3, 71.5, 71.2, 71.1, 70.8, 69.9, 64.2, 62.3, 62.1, 57.5, 
52.3, 37.1, 36.5, 35.2, 34.6, 32.4, 32.2, 31.8, 30.3, 29.8, 
29.7, 29.7, 29.5, 29.4, 29.3, 29.2, 29.0, 27.3, 27.2, 27.1, 
25.9, 25.1, 22.5, 20.7, 14.6, 13.9; υmax: 3364, 2918, 2850, 





(i) The acid 37 (0.054 g, 0.043 mmol) was dissolved in a 
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then warmed gently until all had dissolved. Dry CsHO3 
(0.072 mg, 0.371 mmol) was added to a stirred solution and 
the mixture was left at r. t. for 1 h. then tosylate 52 (0.33 g, 
0.047 mmol) was added. The mixture was stirred at 70 oC 
for 18 h then quenched with water (5 mL). The product was 
extracted with CH2Cl2 (3 × 60 mL) and the combined 
organic layers were dried and evaporated. Chromatogr phy 
(petroleum/EtOAc, 10:1) gave benzyl 2,3,4-tri-O-benzyl-6-
O-(2R,3R,17R,39S,40S,E)-3-hydroxy-39-methoxy-17,40-
dimethyl-2-tetracosyloctapentacont-18-enoate-β-D gluco-
pyranoside 53 (0.056, 70%), []
 +15 (c 1.1, CHCl3) 
[MALDI–Found [M+Na] +: 1798.6; C119H202NaO9 requires: 
1798.5]; δH (400 MHz, CDCl3): 7.4 –7.26 (20H, m), 5.34 
(1H, dt, J 6.4, 15.4 Hz), 5.24 (1H, dd, J 7.4, 15.4 Hz), 4.97 
(1H, d, J 11.0 Hz), 4.95 (1H, d, J 11.0 Hz), 4.93 (1H, d, J
11.0 Hz), 4.9 (1H, d, J 12 Hz), 4.78 (1H, d, J 11 Hz), 4.71 
(1H,  d, J 11 Hz), 4.64 (1H, d, J 12 Hz), 4.61 (1H, d, J 11 
Hz), 4.54 (1H, br t, J 6.4 Hz), 4.52 (1H, br s), 4.22 (1H, dd, 
J 4.6, 11 Hz), 3.67 (2H, br t J 8.7 Hz), 3.54 – 3.47 (3H, m), 
3.35 (3H, s), 2.96 (1H, br pent, J 4.2 Hz), 2.5 – 2.46 (2H, 
m), 2.06 – 2.01 (1H, m), 1.97 (2H, br q, J 6.7 Hz), 1.8 – 1.7 
(1H, m), 1.68 – 1.55 (3H, m), 1.5 – 1.2 (138H, m), 1.15 – 
1.05 (1H, m), 0.94 (3H, d, J 6.7 Hz), 0.89 (6H, t, J 7 Hz), 
0.85 (3H, d, J 6.7 Hz); δC (101 MHz, CDCl3): 175.2, 138.4, 
138.2, 137.7, 137.1, 136.5, 128.5, 128.4, 128.35, 128.1, 
128.0, 127.97, 127.9, 127.85, 127.7, 102.3, 85.4, 84.5, 82.3, 
77.8, 75.8, 75.1, 74.9, 72.8, 72.3, 71.1, 62.9, 57.7, 51.3, 
37.2, 36.7, 35.6, 35.3, 32.6, 32.3, 31.9, 30.5, 30.0, 29.9, 
29.8, 29.7, 29.66, 29.6, 29.58, 29.53, 29.5, 29.4, 29.1, 27.6, 
27.5, 27.4, 26.2, 25.9, 22.7, 20.9, 14.9, 14.1; υmax: 3487, 
2920, 2851, 1738, 1466, 1072, 727, 696 cm-1. 
(ii) Sodium (~50 mg) was added to liq. ammonia (100 mL) 
until the blue colour persisted.  The glucopyranoside 53 (48 
mg, 0.027 mmol) in 1,4-dioxane (2 mL) was added; the
mixture was stirred for 4 – 5 min, when the blue colour 
disappeared, then quenched with sat. aq. NH4Cl (5 mL) and 
ether (30 mL). The ammonia was allowed to evaporate; the 
aqueous layer was extracted with ether (2 × 30 mL). The 
combined organic layers were evaporated. Chromatogrphy 
(CHCl3/MeOH, 10:1) gave a 6:4 α,β-mixture of compound 
54 (18 mg, 47%), 	[]
 +28 (c 0.50, CHCl3) [MALDI–
Found [M+Na]+: 1438.3385; C91H178NaO9 requires: 
1438.3363]; δH (400 MHz, CDCl3 + few drops of CD3OD): 
5.28 (1H, dt, J 6.4, 15.2 Hz), 5.18 (1H, br dd, J 7.4, 15.2 
Hz), 5.1 (0.6H, d, J 3.8 Hz, H–1α), 4.46 (0.4H, d, J 7.8 Hz, 
H–1β), 4.4 (1H, br d, J 11.8 Hz, H–6α,β), 4.24 (1H, br dd, J
5.8, 11.8 Hz, H–6α,β), 3.96 – 3.92 (0.6H, ddd, J 2.2, 5.6, 
9.8 Hz, H–5α), 3.67 – 3.58 (1.6H, H–4α + CH-OH MA), 
3.48 – 3.44 (0.4H, ddd, J 2.2, 5.6, 9.0 Hz, H–5β), 3.43 – 
3.26 (5H, H–2,3α, H–3,4β and s at 3.3 for OCH3), 3.17 
(0.4H, br t, J 8.4 Hz), 2.95 – 2.91 (1H, m), 2.41 – 2.34 (1H, 
m), 2.0 – 1.95 (1H, m), 1.9 (2H, br q, J 6.7 Hz), 1.62 – 1.1 
(146H, m), 1.07 – 1.0 (2H, m), 0.88 (3H, d, J 6.7 Hz), 0.83 
(6H, t, J 6.6 Hz), 0.8 (3H, d, J 7 Hz); δC for α, β isomers 
(400 MHz, CDCl3 + few drops of CD3OD): 175.1, 136.4, 
128.2, 96.6, 92.2, 85.5, 76.1, 74.5, 73.6, 72.4, 72.2, 70.5, 
70.3, 69.2, 63.5, 57.5, 52.7, 52.5, 37.1, 36.6, 35.2, 35.0, 
32.4, 32.2, 31.8, 30.4, 29.8, 29.76, 29.7, 29.6, 29.5, 29.41, 
29.4, 29.3, 29.2, 29.1, 29.0, 27.4, 27.2, 26.0, 22.5, 0.8, 
14.7, 13.9; υmax: 3400, 2923, 2852, 1720, 1466, 1376, 1100 
cm-1. Starting material (12 mg) was recovered.  
 
3.20 Methyl 5-O-[(2R,3R,17R,39S,40S, E)-3-hydroxy-39-
methoxy-17,40-dimethyl-2-tetracosyloctapentacont-18-
enoate]-α-D-arabinofuranoside 57  
 (i) The acid 37 (0.056g, 0.044 mmol) was dissolved in 
THF and DMF (5:1, 1.5 mL) at r. t., then warmed gently 
until all had dissolved. Dry CsHCO3 (0.061mg, 
0.313mmol) was added and stirred at r.t. for 1 h, followed 
by the arabinofuranoside 55 (0.033g, 0.066 mmol)68 in 
THF/ DMF (0.5 mL). The mixture was stirred at 70 oC for 
18 h, quenched with water (3 mL), then extracted with 
CH2Cl2 (3 × 30 mL) and evaporated. Chromatography 
(petroleum/ EtOAc, 10:1) gave methyl 2,3-di-O-benzyl-5-
O-[(2R,3R, 17R,39S,40S,E)-3-hydroxy-39-methoxy-17,40-
di-methyl-2-tetracosyloctapentacont-18-enoate]-α-D
arabinofuranoside 56 (0.049g, 71%) as a colourless thick 
oil, []
 +21 (c 0.51, CHCl3) [MALDI–Found [M+Na]
+: 
1602.3; C105H190NaO8 requires: 1602.4]; δH (400 MHz, 
CDCl3): 7.4 – 7.28 (10H, m), 5.34 (1H, dt, J 6.3, 15.4 Hz), 
5.25 (1H, dd, J 7.4, 15.4 Hz), 4.92 (1H, br s), 4.57 (1H, d, J 
12 Hz), 4.56 (1H, d, J 11.8 Hz), 4.5 (1H, d, J 12.0 Hz), 4.48 
(1H, d, J 11.8 Hz), 4.33 – 4.26 ( 2H, m), 4.24 – 4.2.0 (1H, 
m), 3.99 (1H, d, J 2.1 Hz), 3.84 (1H, dd, J 2.6, 6.5 Hz), 
3.65 – 3.62 (1H, m), 3.37 (3H, s), 3.35 (3H, s), 2.98 – 2.94 
(1H, m), 2.43 (1H, tt, J 5.5, 9.1 Hz), 2.06 – 2.02 (1H, m), 
1.97 (2H, br q, J 6.7 Hz), 1.7 – 1.5 (5H, m), 1.45 – 1.2 
(137H, m), 1.11 – 1.04 (2H, m), 0.94 (3H, d, J 6.7 Hz), 
0.89 (6H, t, J 6.6 Hz), 0.85 (3H, d, J 6.9 Hz); δC (101 MHz, 
CDCl3): 175.0, 137.4, 137.2, 136.4, 128.5, 128.46, 128.4, 
128.0, 127.9, 127.86, 107.2, 87.8, 85.4, 83.7, 79.4, 72.4, 
72.2, 72.1, 63.5, 57.7, 54.9, 51.5, 37.2, 36.7, 35.5, 35.3, 
32.6, 32.3, 31.9, 30.5, 30.0, 29.9, 29.7, 29.6, 29.5, 29.4, 
29.35, 29.1, 27.6, 27.4, 27.36, 26.2, 25.8, 22.7, 20.9, 14.9, 
14.1; υmax: 2923, 2853, 1738, 1465, 1100 cm
-1. 
 (ii) Sodium (50 mg) was added toliq. ammonia (100 mL) 
as above. Arabinofuranoside 56 (42 mg, 0.026 mmol) in 
1,4-dioxane (2 mL) was added and stirred for 4 – 5 min, 
when the blue colour disappeared, then quenched with sat. 
aq. NH4Cl (5 mL) and ether (30 mL). Work up as before 
and chromatography (CHCl3/MeOH, 10:1) gave compound 
57 as a thick oil (21 mg, 57%), []
 +26 (c 0.70, CHCl3) 
[MALDI–Found [M+Na]+: 1422.3430; C91H178NaO8 
requires: 1422.3414]. This showed δH (400 MHz, CDCl3 + 
few drops of CD3OD): 5.28 (1H, dt, J 6.4, 15.2 Hz), 5.2 
(1H, dd, J 7.4, 15.2 Hz), 4.78 (1H, br s), 4.33 (1H, dd, J 
4.6, 11.7 Hz), 4.28 (1H, dd, J 5, 11.7 Hz), 4.08 (1H, br q, J 
4.9 Hz), 3.96 (1H, dd, J 1.3, 2.8 Hz), 3.85 (1H, dd, J 2.9, 
5.0 Hz), 3.65 – 3.60 (1H, m), 3.35 (3H, s), 3.3 (3H, s), 2.95 
– 2.93 (1H, m), 2.39 (1H, ddd, J 4.8, 7.4, 10.2 Hz), 2.01 – 
1.96 (1H, m), 1.91 (2H, br q, J 6.6 Hz), 1.62 – 1.03 (146H, 
m), 0.89  (3H, d, J 6.7 Hz), 0.84 (6H, t, J 6.6 Hz), 0.8 (3H, 
d, J 7.0 Hz); δC (101 MHz, CDCl3 + few drops of CD3OD): 
175.0, 136.4, 128.3, 108.8, 85.5, 81.9, 81.2, 78.0, 72.4, 
63.4, 57.6, 55.0, 52.6, 37.1, 36.6, 35.2, 34.9, 32.4, 32.2, 
31.8, 30.4, 29.8, 29.78, 29.7, 29.6, 29.5, 29.48, 29.4, 29.3, 
29.2, 20.0, 27.4, 27.3, 27.2, 26.0, 25.3, 22.6, 20.8, 14.7, 
14.0; νmax: 3400, 2925, 2854, 1724, 1466, 1215, 1094 cm
-1. 
Starting material (10.2 mg) was recovered. 
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(i) CsHCO3 (0.061 g, 0.313 mmol) was added to a solution 
of tosylate 58 (0.030 g, 0.067 mmol)69 and acid 37 (0.056 
g, 0.044 mmol) in dry DMF:THF (1:5, 2 mL) at r. t. and 
stirred at 70 oC for two days. The suspension was diluted 
with EtOAc (20 mL) and water (10 mL) and the aqueous 
layer was extracted with EtOAc (3 × 10 mL). The 
combined organic layers were washed with water (10 mL)
and brine (10 mL), dried and evaporated to give a thick oil. 
Column chromatography (10:1 hexane/EtOAc) gave (S)-
2,3-bis-(benzyloxy)propyl (2R,3R,17R,39S,40S,E)-3-
hydroxy-39-methoxy-17,40-dimethyl-2-tetracosylocta-
pentacont-18-enoate 59 (0.060, 89%) [MALDI–Found 
[M+Na]+: 1530.3; C102H186NaO6 requires: 1530.4]. This 
showed δH (400 MHz, CDCl3): 7.4 – 7.28 (10H, m), 5.34 
(1H, dt, J 6.4, 15.3 Hz), 5.25 (1H, dd, J 7.4, 15.3 Hz), 4.7 
(1H, d, J 12.0 Hz), 4.65 (1H, d, J 12.0 Hz), 4.6 (2H, br s), 
4.44 (1H, dd, J 4, 11.6 Hz), 4.23 (1H, dd, J 5.4, 11.6 Hz), 
3.84 (1H, br pent, J 5.4 Hz), 3.64 – 3.57 (3H, m), 3.36 (3H, 
s), 2.99 – 2.96 (1H, m), 2.5 (1H, br d, J 5.9 Hz), 2.44 ( 1H, 
br td, J 5.4, 9.8 Hz), 2.1–2.03 (1H, m), 1.98 (2H, br q, J 6.7 
Hz), 1.73 – 1.2 (142H, br m), 1.15 – 1.07 (1H, m), 0.96 
(3H, d, J 6.7 Hz), 0.9  (6H, t, J 6.7 Hz), 0.87 (3H, d, J 6.9 
Hz); δC (101 MHz, CDCl3): 175.4, 138.0, 137.9, 136.5, 
128.4, 128.35, 127.73, 127.7, 127.6, 85.4, 75.8, 73.5, 72.3, 
72.1, 69.6, 63.5, 57.7, 51.4, 37.2, 36.7, 35.5, 35.3, 32.6, 
32.4, 31.9, 30.5, 30.0, 29.9, 29.8, 29.7, 29.66, 29.6, 29.5, 
29.44, 29.4, 29.1, 27.6, 27.5, 27.4, 26.2, 25.8, 22.7, 0.9, 
14.9, 14.1; υmax: 3474, 2924, 2853, 1735, 1466, 1370, 1100, 
968, 908 cm-1. 
(ii)  Sodium (~50 mg) was added to liq. ammonia (100 mL) 
as above. Ester 59 (52 mg, 0.034 mmol) in 1,4-dioxane (2 
mL) was added. The mixture was stirred for 4 – 5 min., 
when the blue colour disappeared, then quenched with
NH4Cl (5 mL) and ether (30 mL). Work up as before and 
chroma-tography (CHCl3/MeOH, 10:1) gave compound 60 
(18 mg, 40%) [MALDI–Found [M+Na]+: 1350.3215; 
C88H174NaO6 requires: 1350.3203]; δH (400 MHz, CDCl3 + 
few drops of CD3OD): 5.33 (1H, dt, J 6.4, 15.3 Hz), 5.23 
(1H, dd, J 7.4, 15.3 Hz), 4.27 (1H, dd, J 4.2, 11.5 Hz), 4.21 
(1H, dd, J 6.4, 11.5 Hz), 3.96 – 3.91 (1H, m), 3.71 – 3.65 
(2H, m), 3.61 (1H, br dd, J 5.5, 11.5 Hz), 3.34 ( 3H, s), 
2.97 – 2.94 (1H, br, m), 2.48 –2.42 (1H, m), 2.06-2.01 (1H, 
m), 1.96  (2H, br q, J 6.6 Hz), 1.71 – 1.05 (146 H, m), 0.93  
(3H, d, J 6.7 Hz), 0.88 (6 H, t, J 6.6 Hz), 0.84 (3H, d, J 6.9 
Hz); δC (101 MHz, CDCl3 + few drops of CD3OD): 175.5, 
136.4, 128.3, 85.5, 72.6, 69.8, 65.1, 63.0, 57.6, 52.5, 37.1, 
36.6, 35.2, 35.0, 32.5, 32.3, 31.8, 30.4, 29.9, 29.8, 29.7, 
29.6, 29.55, 29.52, 29.5, 29.4, 29.3, 29.25, 29.0, 27.4, 
27.36, 27.3, 26.0, 25.3, 22.6, 20.8, 14.7, 14.0; υmax: 3434, 
2922, 2853, 1722, 1465, 1099 cm-1. Starting material (10 
mg) was recovered. 
 
3.22 ELISA method 
ELISA were carried out on 96-well flat-bottomed polystyrene 
micro-plates.  Antigens were dissolved in hexane to give a 
concentration 15 µg/ml.  50 µl of this solution was added to 
each well, and the solvent was left to evaporate at r. t.. Control 
wells were coated with hexane (50 µl / well) only.  Blocking 
was done by adding 400 µl of 0.5 % casein/PBS buffer (pH = 
7.4) to each well, and the plates were incubated at 25 ºC for 30 
minutes.  The buffer was aspirated and any excess flicked out 
until the plates were dry.  Serum (1 in 40 dilution in 
casein/PBS buffer) (50 µl / well) was added and incubated at 
25 ºC for 1 h.  The plates were washed with 400 µl casein/PBS 
buffer 3 times using an automatic washer, and any excess 
flicked out onto a paper towel until dry.  Secondary ntibody 
(anti-human IgG (Fc specific) peroxidise conjugated antibody 
produced in goat (Aldrich) (diluted to 1:2000 in casein/PBS 
buffer) (50 µl / well) was added, and incubated at 25 ºC for 30 
minutes.  The plates were again washed 3 times with 400 µl 
casein/PBS buffer using an automatic washer, and any excess 
was again flicked out.  OPD substrate (o-phenylenediamine, 1 
mg/ml, 50 µl / well) and H2O2 (0.8 mg/ml) in 0.1 M citrate 
buffer) was added, and the plates were incubated for 30 
minutes at 25 ºC.  The colour reaction was terminated by 
adding 2.5 M H2SO4 (50 µl / well), and the absorbance 
measured at 492nm. 
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